poai20211231_10k.htm
0001446159 Predictive Oncology Inc. false --12-31 FY 2021 0 244,830 20,000,000 20,000,000 0.01 0.01 2,300,000 2,300,000 79,246 79,246 0.01 0.01 200,000,000 100,000,000 65,614,597 19,804,787 145,831 0 0 5 5.5 5 5.5 0 80,000 4 10 200,000 10 3,500,000 1 1 5.5 5 3 5.5 3 10 5.5 2 5.5 5.5 0.1 3 10 0.72 1.10 1.15 1.64 2.610 8.41 10.10 5,962.50 80 1.72 1.80 2.18 2.25 10.00 10.71 22.50 0 0 0 0 0 0 3 3 0 100 4.0 0 0 Sale price includes one share and a warrant to purchase one-half share. The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term. 00014461592021-01-012021-12-31 iso4217:USD 00014461592021-06-30 xbrli:shares 00014461592022-03-24 thunderdome:item 00014461592021-12-31 00014461592020-12-31 iso4217:USDxbrli:shares 0001446159poai:SeriesBConvertiblePreferredStockMember2021-12-31 0001446159poai:SeriesBConvertiblePreferredStockMember2020-12-31 00014461592020-01-012020-12-31 0001446159poai:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-12-31 0001446159poai:SeriesDConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-12-31 0001446159poai:SeriesEConvertiblePreferredStockMemberus-gaap:PreferredStockMember2019-12-31 0001446159us-gaap:CommonStockMember2019-12-31 0001446159us-gaap:AdditionalPaidInCapitalMember2019-12-31 0001446159us-gaap:RetainedEarningsMember2019-12-31 00014461592019-12-31 0001446159us-gaap:CommonStockMember2020-01-012020-12-31 0001446159us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0001446159poai:WarrantsIssuedPursuantTo2020ConvertibleDebtMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0001446159poai:WarrantsIssuedPursuantTo2020ConvertibleDebtMember2020-01-012020-12-31 0001446159poai:BridgeNotesMemberus-gaap:CommonStockMember2020-01-012020-12-31 0001446159poai:BridgeNotesMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0001446159poai:BridgeNotesMember2020-01-012020-12-31 0001446159poai:SeriesEPreferredStockConversionsMemberpoai:SeriesEConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-31 0001446159poai:SeriesEPreferredStockConversionsMemberus-gaap:CommonStockMember2020-01-012020-12-31 0001446159poai:SeriesEPreferredStockConversionsMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0001446159poai:WarrantsIssuedPursuantTo2020ConvertibleDebt2Memberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0001446159poai:WarrantsIssuedPursuantTo2020ConvertibleDebt2Member2020-01-012020-12-31 0001446159poai:ConversionOfSeriesDPreferredStockToCommonStockMemberpoai:SeriesDConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-31 0001446159poai:ConversionOfSeriesDPreferredStockToCommonStockMemberus-gaap:CommonStockMember2020-01-012020-12-31 0001446159poai:ConversionOfSeriesDPreferredStockToCommonStockMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0001446159poai:PrefundedWarrantsMemberus-gaap:CommonStockMember2020-01-012020-12-31 0001446159poai:PrefundedWarrantsMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0001446159poai:PrefundedWarrantsMember2020-01-012020-12-31 0001446159us-gaap:CommonStockMemberpoai:May2020OfferingMember2020-01-012020-12-31 0001446159us-gaap:AdditionalPaidInCapitalMemberpoai:May2020OfferingMember2020-01-012020-12-31 0001446159poai:May2020OfferingMember2020-01-012020-12-31 0001446159poai:June2020WarrantMemberpoai:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-31 0001446159poai:June2020WarrantMemberpoai:SeriesDConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-31 0001446159poai:June2020WarrantMemberpoai:SeriesEConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-31 0001446159poai:June2020WarrantMemberus-gaap:CommonStockMember2020-01-012020-12-31 0001446159poai:June2020WarrantMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0001446159poai:June2020WarrantMemberus-gaap:RetainedEarningsMember2020-01-012020-12-31 0001446159poai:June2020WarrantMember2020-01-012020-12-31 0001446159poai:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-31 0001446159poai:SeriesDConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-31 0001446159poai:SeriesEConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-12-31 0001446159us-gaap:RetainedEarningsMember2020-01-012020-12-31 0001446159poai:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-12-31 0001446159poai:SeriesDConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-12-31 0001446159poai:SeriesEConvertiblePreferredStockMemberus-gaap:PreferredStockMember2020-12-31 0001446159us-gaap:CommonStockMember2020-12-31 0001446159us-gaap:AdditionalPaidInCapitalMember2020-12-31 0001446159us-gaap:RetainedEarningsMember2020-12-31 0001446159poai:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2021-01-012021-12-31 0001446159us-gaap:CommonStockMember2021-01-012021-12-31 0001446159us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-31 0001446159us-gaap:RetainedEarningsMember2021-01-012021-12-31 0001446159poai:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberpoai:RegisteredDirectOfferingsMember2021-01-012021-12-31 0001446159us-gaap:CommonStockMemberpoai:RegisteredDirectOfferingsMember2021-01-012021-12-31 0001446159us-gaap:AdditionalPaidInCapitalMemberpoai:RegisteredDirectOfferingsMember2021-01-012021-12-31 0001446159us-gaap:RetainedEarningsMemberpoai:RegisteredDirectOfferingsMember2021-01-012021-12-31 0001446159poai:RegisteredDirectOfferingsMember2021-01-012021-12-31 0001446159poai:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberus-gaap:PrivatePlacementMember2021-01-012021-12-31 0001446159us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2021-01-012021-12-31 0001446159us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2021-01-012021-12-31 0001446159us-gaap:RetainedEarningsMemberus-gaap:PrivatePlacementMember2021-01-012021-12-31 0001446159us-gaap:PrivatePlacementMember2021-01-012021-12-31 0001446159poai:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMemberpoai:June2021OfferingMember2021-01-012021-12-31 0001446159us-gaap:CommonStockMemberpoai:June2021OfferingMember2021-01-012021-12-31 0001446159us-gaap:AdditionalPaidInCapitalMemberpoai:June2021OfferingMember2021-01-012021-12-31 0001446159us-gaap:RetainedEarningsMemberpoai:June2021OfferingMember2021-01-012021-12-31 0001446159poai:June2021OfferingMember2021-01-012021-12-31 0001446159poai:SeriesBConvertiblePreferredStockMemberus-gaap:PreferredStockMember2021-12-31 0001446159us-gaap:CommonStockMember2021-12-31 0001446159us-gaap:AdditionalPaidInCapitalMember2021-12-31 0001446159us-gaap:RetainedEarningsMember2021-12-31 0001446159poai:StockIssuedForConvertibleDebtMember2021-01-012021-12-31 0001446159poai:StockIssuedForConvertibleDebtMember2020-01-012020-12-31 0001446159poai:StockIssuedForDebtMember2021-01-012021-12-31 0001446159poai:StockIssuedForDebtMember2020-01-012020-12-31 0001446159poai:ConversionOfSeriesDPreferredStockToCommonStockMember2021-01-012021-12-31 0001446159poai:ConversionOfSeriesDPreferredStockToCommonStockMember2020-01-012020-12-31 0001446159poai:ConversionOfSeriesEPreferredStockMember2021-01-012021-12-31 0001446159poai:ConversionOfSeriesEPreferredStockMember2020-01-012020-12-31 utr:Y 0001446159us-gaap:OfficeEquipmentMembersrt:MinimumMember2021-01-012021-12-31 0001446159us-gaap:OfficeEquipmentMembersrt:MaximumMember2021-01-012021-12-31 0001446159us-gaap:LeaseholdImprovementsMembersrt:MinimumMember2021-01-012021-12-31 0001446159us-gaap:LeaseholdImprovementsMembersrt:MaximumMember2021-01-012021-12-31 0001446159poai:ManufacturingToolingMembersrt:MinimumMember2021-01-012021-12-31 0001446159poai:ManufacturingToolingMembersrt:MaximumMember2021-01-012021-12-31 0001446159poai:LaboratoryEquipmentMembersrt:MinimumMember2021-01-012021-12-31 0001446159poai:LaboratoryEquipmentMembersrt:MaximumMember2021-01-012021-12-31 0001446159poai:DemoEquipmentMember2021-01-012021-12-31 0001446159us-gaap:OtherIntangibleAssetsMember2021-01-012021-12-31 xbrli:pure 0001446159srt:MinimumMember2021-01-012021-12-31 0001446159srt:MaximumMember2021-01-012021-12-31 0001446159srt:MinimumMember2020-01-012020-12-31 0001446159srt:MaximumMember2020-01-012020-12-31 0001446159us-gaap:MeasurementInputExpectedDividendRateMember2021-12-31 0001446159us-gaap:MeasurementInputExpectedDividendRateMember2020-12-31 0001446159us-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2021-12-31 0001446159us-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2021-12-31 0001446159us-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2020-12-31 0001446159us-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2020-12-31 0001446159us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2021-12-31 0001446159us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2021-12-31 0001446159us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2020-12-31 0001446159us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2020-12-31 0001446159us-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2021-12-31 0001446159us-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2021-12-31 0001446159us-gaap:MeasurementInputExpectedTermMembersrt:MinimumMember2020-12-31 0001446159us-gaap:MeasurementInputExpectedTermMembersrt:MaximumMember2020-12-31 0001446159poai:ZPREDICTAMember2021-11-242021-11-24 0001446159poai:ZPREDICTAMember2021-01-012021-12-31 0001446159poai:ZPREDICTAMember2021-11-24 0001446159poai:ZPREDICTAMemberus-gaap:TradeNamesMember2021-11-24 0001446159poai:ZPREDICTAMemberpoai:DevelopedTechnologyMember2021-11-24 0001446159poai:ZPREDICTAMemberus-gaap:CustomerRelationshipsMember2021-11-24 0001446159poai:ZPREDICTAMemberus-gaap:TradeNamesMember2021-01-012021-12-31 0001446159poai:ZPREDICTAMemberpoai:DevelopedTechnologyMember2021-01-012021-12-31 0001446159poai:ZPREDICTAMemberus-gaap:CustomerRelationshipsMember2021-01-012021-12-31 0001446159poai:ZPREDICTAMember2020-01-012020-12-31 00014461592021-08-17 0001446159poai:RegisteredDirectOfferingsMember2021-01-012021-02-28 0001446159us-gaap:PrivatePlacementMember2021-01-012021-02-28 0001446159poai:InvestorWarrantsMemberpoai:RegisteredDirectOfferingsMember2021-02-28 00014461592021-02-28 0001446159poai:PlacementAgentWarrantsMember2021-02-28 0001446159poai:PlacementAgentWarrantsMemberpoai:RegisteredDirectOfferingsMember2021-02-28 0001446159poai:PlacementAgentWarrantsMemberpoai:June2021OfferingMember2021-02-28 0001446159poai:PlacementAgentWarrantsMemberus-gaap:PrivatePlacementMember2021-02-28 0001446159poai:January122021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:January122021RegisteredDirectOfferingMember2021-12-31 0001446159poai:InvestorWarrantsMemberpoai:January122021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:InvestorWarrantsMemberpoai:January122021RegisteredDirectOfferingMember2021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:January122021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:January122021RegisteredDirectOfferingMember2021-12-31 0001446159poai:January212021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:January212021RegisteredDirectOfferingMember2021-12-31 0001446159poai:InvestorWarrantsMemberpoai:January212021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:InvestorWarrantsMemberpoai:January212021RegisteredDirectOfferingMember2021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:January212021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:January212021RegisteredDirectOfferingMember2021-12-31 0001446159poai:January262021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:January262021RegisteredDirectOfferingMember2021-12-31 0001446159poai:InvestorWarrantsMemberpoai:January262021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:InvestorWarrantsMemberpoai:January262021RegisteredDirectOfferingMember2021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:January262021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:January262021RegisteredDirectOfferingMember2021-12-31 0001446159poai:February162021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:February162021RegisteredDirectOfferingMember2021-12-31 0001446159poai:InvestorWarrantsMemberpoai:February162021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:InvestorWarrantsMemberpoai:February162021RegisteredDirectOfferingMember2021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:February162021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:February162021RegisteredDirectOfferingMember2021-12-31 0001446159poai:Febuary232021PrivatePlacementMember2021-01-012021-12-31 0001446159poai:Febuary232021PrivatePlacementMember2021-12-31 0001446159poai:InvestorWarrantsMemberpoai:Febuary232021PrivatePlacementMember2021-01-012021-12-31 0001446159poai:InvestorWarrantsMemberpoai:Febuary232021PrivatePlacementMember2021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:Febuary232021PrivatePlacementMember2021-01-012021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:Febuary232021PrivatePlacementMember2021-12-31 0001446159poai:June162021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:June162021RegisteredDirectOfferingMember2021-12-31 0001446159poai:InvestorWarrantsMemberpoai:June162021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:InvestorWarrantsMemberpoai:June162021RegisteredDirectOfferingMember2021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:June162021RegisteredDirectOfferingMember2021-01-012021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:June162021RegisteredDirectOfferingMember2021-12-31 0001446159poai:TotalIssuancesMember2021-01-012021-12-31 0001446159poai:InvestorWarrantsMemberpoai:TotalIssuancesMember2021-01-012021-12-31 0001446159poai:PlacementAgentWarrantsMemberpoai:TotalIssuancesMember2021-01-012021-12-31 0001446159poai:InvestorWarrantsMember2021-01-012021-12-31 0001446159poai:InvestorWarrantsMember2021-12-31 0001446159poai:EquityLinePurchaseAgreementMember2019-10-242019-10-24 0001446159poai:EquityIncentivePlanMembersrt:MaximumMember2021-01-012021-09-30 0001446159poai:EquityLinePurchaseAgreementMember2020-01-012020-12-31 0001446159poai:EquityLinePurchaseAgreementMember2021-12-31 0001446159poai:EquityLinePurchaseAgreementMember2021-01-012021-12-31 0001446159us-gaap:SeriesDPreferredStockMember2019-04-30 0001446159us-gaap:SeriesDPreferredStockMember2019-04-012019-04-30 0001446159poai:ConversionFromSeriesDPreferredStockToCommonStockMember2020-04-042020-04-04 0001446159poai:SeriesEConvertiblePreferredStockMember2019-06-012019-09-30 0001446159poai:ConversionFromSeriesEPreferredStockToCommonStockMember2020-01-012020-03-31 0001446159poai:ConversionFromSeriesEPreferredStockToCommonStockMember2020-05-012020-05-31 0001446159poai:ConversionFromSeriesEPreferredStockToCommonStockMember2020-06-12 0001446159poai:ConversionFromSeriesEPreferredStockToCommonStockMember2020-06-122020-06-12 0001446159us-gaap:PrivatePlacementMember2020-03-182020-03-18 0001446159us-gaap:PrivatePlacementMember2020-03-18 0001446159poai:WarrantsIssuedWithPrivatePlacementMember2020-03-18 0001446159poai:WarrantsIssuedWithPrivatePlacementMember2020-03-182020-03-18 0001446159poai:SeriesAWarrantsMember2020-03-18 0001446159poai:SeriesBWarrantsMember2020-03-18 0001446159poai:PrefundedWarrantMember2020-03-18 0001446159poai:PrefundedWarrantMember2020-03-012020-03-18 0001446159us-gaap:PrivatePlacementMember2020-03-012020-03-18 0001446159poai:June2020WarrantMember2020-09-23 0001446159poai:DrschwartzNotesMember2020-04-21 0001446159poai:ConversionOfPromissoryNoteIntoCommonStockMemberpoai:DrschwartzNotesMember2020-04-212020-04-21 0001446159poai:ConversionOfPromissoryNoteIntoCommonStockMember2020-04-21 0001446159us-gaap:PrivatePlacementMember2020-05-082020-05-08 0001446159us-gaap:PrivatePlacementMember2020-05-08 0001446159poai:WarrantsIssuedWithPrivatePlacementMember2020-05-08 0001446159poai:WarrantsIssuedWithPrivatePlacementMember2020-05-082020-05-08 0001446159poai:AssetPurchaseAgreementWithInventabiotechAndItsSubsidiariesSolubleAndBiodethMember2020-05-272020-05-27 0001446159poai:AssetPurchaseAgreementWithInventabiotechAndItsSubsidiariesSolubleAndBiodethMember2020-05-27 0001446159us-gaap:OtherCapitalizedPropertyPlantAndEquipmentMember2020-05-27 0001446159poai:WarrantIssuedInConnectionWithMay2020OfferingMember2020-06-012020-06-30 0001446159poai:WarrantIssuedInConnectionWithMay2020OfferingMember2020-06-30 0001446159poai:June2020WarrantMember2020-06-30 0001446159poai:June2020WarrantMember2020-06-012020-06-30 00014461592020-09-23 0001446159poai:AssetPurchaseAgreementWithQuantitativeMedicineMember2020-07-012020-07-01 0001446159poai:AssetPurchaseAgreementWithQuantitativeMedicineMemberpoai:CarnegieMellonUniversityMember2020-07-012020-07-01 0001446159poai:WarrantsIssuedInConnectionWithHelomicsAcquisitionMember2020-09-14 00014461592020-09-14 0001446159poai:WarrantsIssuedInConnectionWithHelomicsAcquisitionMember2019-10-29 0001446159poai:ReverseStockSplitMember2019-10-292019-10-29 0001446159poai:WarrantsIssuedInConnectionWithHelomicsAcquisitionMember2020-09-142020-09-14 0001446159us-gaap:EmployeeStockOptionMembersrt:MaximumMember2021-01-012021-12-31 0001446159poai:StockIncentivePlan2012Member2021-06-30 0001446159poai:StockIncentivePlan2012Member2021-08-10 0001446159us-gaap:EmployeeStockOptionMember2019-12-31 0001446159us-gaap:WarrantMember2019-12-31 0001446159us-gaap:EmployeeStockOptionMember2020-01-012020-12-31 0001446159us-gaap:WarrantMember2020-01-012020-12-31 0001446159us-gaap:EmployeeStockOptionMember2020-12-31 0001446159us-gaap:WarrantMember2020-12-31 0001446159us-gaap:EmployeeStockOptionMember2021-01-012021-12-31 0001446159us-gaap:WarrantMember2021-01-012021-12-31 0001446159us-gaap:EmployeeStockOptionMember2021-12-31 0001446159us-gaap:WarrantMember2021-12-31 0001446159poai:StockOptionsOneMember2021-01-012021-12-31 0001446159poai:StockOptionsOneMember2021-12-31 0001446159poai:StockOptionsTwoMember2021-01-012021-12-31 0001446159poai:StockOptionsTwoMember2021-12-31 0001446159poai:StockOptionsThreeMember2021-01-012021-12-31 0001446159poai:StockOptionsThreeMember2021-12-31 0001446159poai:StockOptionsFourMember2021-01-012021-12-31 0001446159poai:StockOptionsFourMember2021-12-31 0001446159poai:WarrantOneMembersrt:MinimumMember2021-12-31 0001446159poai:WarrantOneMembersrt:MaximumMember2021-12-31 0001446159poai:WarrantOneMember2021-12-31 0001446159poai:WarrantOneMember2021-01-012021-12-31 0001446159poai:WarrantTwoMembersrt:MinimumMember2021-12-31 0001446159poai:WarrantTwoMembersrt:MaximumMember2021-12-31 0001446159poai:WarrantTwoMember2021-12-31 0001446159poai:WarrantTwoMember2021-01-012021-12-31 0001446159poai:WarrantThreeMembersrt:MinimumMember2021-12-31 0001446159poai:WarrantThreeMembersrt:MaximumMember2021-12-31 0001446159poai:WarrantThreeMember2021-12-31 0001446159poai:WarrantThreeMember2021-01-012021-12-31 0001446159poai:WarrantFourMembersrt:MinimumMember2021-12-31 0001446159poai:WarrantFourMembersrt:MaximumMember2021-12-31 0001446159poai:WarrantFourMember2021-12-31 0001446159poai:WarrantFourMember2021-01-012021-12-31 0001446159poai:StockOptions2012Member2021-12-31 0001446159poai:StockOptions2012Membersrt:MinimumMember2021-12-31 0001446159poai:StockOptions2012Membersrt:MaximumMember2021-12-31 0001446159poai:StockOptions2013Member2021-12-31 0001446159poai:StockOptions2013Membersrt:MinimumMember2021-12-31 0001446159poai:StockOptions2013Membersrt:MaximumMember2021-12-31 0001446159poai:StockOptions2014Member2021-12-31 0001446159poai:StockOptions2014Membersrt:MinimumMember2021-12-31 0001446159poai:StockOptions2014Membersrt:MaximumMember2021-12-31 0001446159poai:StockOptions2015Member2021-12-31 0001446159poai:StockOptions2015Membersrt:MinimumMember2021-12-31 0001446159poai:StockOptions2015Membersrt:MaximumMember2021-12-31 0001446159poai:StockOptions2016Member2021-12-31 0001446159poai:StockOptions2016Membersrt:MinimumMember2021-12-31 0001446159poai:StockOptions2016Membersrt:MaximumMember2021-12-31 0001446159poai:StockOptions2017Member2021-12-31 0001446159poai:StockOptions2017Membersrt:MinimumMember2021-12-31 0001446159poai:StockOptions2017Membersrt:MaximumMember2021-12-31 0001446159poai:StockOptions2018Member2021-12-31 0001446159poai:StockOptions2018Membersrt:MinimumMember2021-12-31 0001446159poai:StockOptions2018Membersrt:MaximumMember2021-12-31 0001446159poai:StockOptions2019Member2021-12-31 0001446159poai:StockOptions2019Membersrt:MinimumMember2021-12-31 0001446159poai:StockOptions2019Membersrt:MaximumMember2021-12-31 0001446159poai:StockOptions2020Member2021-12-31 0001446159poai:StockOptions2020Membersrt:MinimumMember2021-12-31 0001446159poai:StockOptions2020Membersrt:MaximumMember2021-12-31 0001446159poai:StockOptions2021Member2021-12-31 0001446159poai:StockOptions2021Membersrt:MinimumMember2021-12-31 0001446159poai:StockOptions2021Membersrt:MaximumMember2021-12-31 0001446159srt:MinimumMember2021-12-31 0001446159srt:MaximumMember2021-12-31 0001446159poai:Warrants2017Member2021-12-31 0001446159poai:Warrants2017Membersrt:MinimumMember2021-12-31 0001446159poai:Warrants2017Membersrt:MaximumMember2021-12-31 0001446159poai:Warrants2018Member2021-12-31 0001446159poai:Warrants2018Membersrt:MinimumMember2021-12-31 0001446159poai:Warrants2018Membersrt:MaximumMember2021-12-31 0001446159poai:Warrants2019Member2021-12-31 0001446159poai:Warrants2019Membersrt:MinimumMember2021-12-31 0001446159poai:Warrants2019Membersrt:MaximumMember2021-12-31 0001446159poai:Warrants2020Member2021-12-31 0001446159poai:Warrants2020Membersrt:MinimumMember2021-12-31 0001446159poai:Warrants2020Membersrt:MaximumMember2021-12-31 0001446159poai:Warrants2021Member2021-12-31 0001446159poai:Warrants2021Membersrt:MinimumMember2021-12-31 0001446159poai:Warrants2021Membersrt:MaximumMember2021-12-31 0001446159poai:PromissoryNotesReceivableMemberpoai:CytoBioscienceMember2019-12-31 0001446159poai:ConvertiblePromissoryNoteMember2021-12-31 0001446159poai:ConvertiblePromissoryNoteMember2020-12-31 0001446159poai:PromissoryNoteOneMember2021-12-31 0001446159poai:PromissoryNoteOneMember2020-12-31 0001446159poai:PromissoryNoteTwoMember2021-12-31 0001446159poai:PromissoryNoteTwoMember2020-12-31 0001446159poai:BridgeNotesMemberpoai:ConvertiblePromissoryNoteMember2018-09-28 0001446159poai:BridgeNotesMemberpoai:ConvertiblePromissoryNoteMember2018-09-282018-09-28 0001446159poai:BridgeLoanWarrantsMember2018-09-28 0001446159poai:BridgeNotesMemberpoai:ConvertiblePromissoryNoteMember2019-02-012019-02-27 0001446159poai:BridgeNotesMemberpoai:ConvertiblePromissoryNoteMember2020-01-012020-12-31 0001446159poai:ConversionOfBridgeLoanToCommonStockMember2020-01-012020-12-31 0001446159poai:SecuritiesPurchaseAgreementsMemberpoai:PromissoryNoteMember2019-09-30 0001446159poai:SecuritiesPurchaseAgreementsMemberpoai:PromissoryNoteMember2019-09-012019-09-30 0001446159poai:WarrantForPromissoryNotesMember2019-09-30 0001446159poai:SecuritiesPurchaseAgreementsMemberpoai:PromissoryNoteMember2020-03-19 0001446159poai:SecuritiesPurchaseAgreementsMemberpoai:PromissoryNoteMember2020-03-192020-03-19 0001446159poai:SecuritiesPurchaseAgreementsMemberpoai:PromissoryNoteMember2020-01-012020-03-31 0001446159poai:SecuritiesPurchaseAgreementsMemberpoai:PromissoryNoteMember2020-07-012020-09-30 0001446159poai:SecuritiesPurchaseAgreementsMemberpoai:MaturityExtensionToMarch312021Memberpoai:PromissoryNoteMember2020-07-012020-09-30 0001446159poai:SecuritiesPurchaseAgreementsMemberpoai:PromissoryNoteMember2020-10-012020-12-31 0001446159poai:SecuritiesPurchaseAgreementsMemberpoai:PromissoryNoteMember2020-01-012020-12-31 0001446159poai:SecuritiesPurchaseAgreementsMemberpoai:PromissoryNoteMember2020-12-31 0001446159poai:SecondPromissoryNoteMember2020-02-05 0001446159poai:SecondPromissoryNoteMember2020-02-052020-02-05 0001446159poai:SecuritiesPurchaseAgreementsMemberpoai:SecondPromissoryNoteMember2020-07-012020-09-30 0001446159poai:SecuritiesPurchaseAgreementsMemberpoai:MaturityExtensionToMarch312021Memberpoai:SecondPromissoryNoteMember2020-07-012020-09-30 0001446159poai:WarrantsIssuedWithPromissoryNoteOneMember2020-02-05 0001446159poai:WarrantsIssuedWithPromissoryNoteTwoMember2020-03-05 0001446159poai:WarrantsIssuedWithPromissoryNoteThreeMember2020-04-05 0001446159poai:WarrantsIssuedWithPromissoryNoteMember2020-02-05 0001446159poai:InvestorOfPromissoryNoteMember2020-02-052020-02-05 0001446159poai:SecondPromissoryNoteMember2020-10-012020-12-31 0001446159poai:SecondPromissoryNoteMember2020-01-012020-12-31 0001446159poai:SecondPromissoryNoteMember2020-12-31 0001446159poai:DebtIssuedInSeptember2018September2019AndFebruary2020Member2021-03-012021-03-01 0001446159poai:DrSchwartzNoteOneMember2018-11-012018-11-30 0001446159poai:DrSchwartzNoteOneMember2018-12-31 0001446159poai:DrschwartzNotesMember2019-07-15 0001446159poai:DrSchwartzNotesWarrantsMember2019-07-15 0001446159poai:PromissoryNoteExchangeAgreementMembersrt:ChiefExecutiveOfficerMember2020-01-012020-01-31 0001446159srt:ChiefExecutiveOfficerMemberpoai:PromissoryNoteMember2020-01-31 0001446159srt:ChiefExecutiveOfficerMember2020-01-012020-01-31 0001446159poai:DrschwartzNotesMember2020-01-31 0001446159poai:DrSchwartzMember2020-04-21 0001446159poai:DrSchwartzMemberpoai:DrschwartzNotesMember2021-02-242021-02-24 0001446159poai:DrSchwartzMember2021-02-242021-02-24 0001446159poai:BorrowingsAgainstEquityLineMember2020-12-31 0001446159poai:BorrowingsAgainstEquityLineMember2020-01-012020-12-31 0001446159poai:PaycheckProtectionProgramCaresActMember2020-04-202020-04-20 0001446159poai:PromissoryNote2020ConversionFeatureTrancheOneMember2020-02-05 0001446159poai:PromissoryNote2020ConversionFeatureTrancheTwoMember2020-02-05 0001446159poai:PromissoryNote2020ConversionFeatureTrancheThreeMember2020-02-05 0001446159poai:PromissoryNote2020ConversionFeatureMember2020-01-012020-12-31 0001446159poai:PromissoryNote2020ConversionFeatureMember2021-03-01 0001446159poai:PromissoryNote2020ConversionFeatureMember2021-12-31 0001446159poai:PromissoryNote2020ConversionFeatureMember2020-12-31 0001446159poai:ABAndAgentWarrantsMember2020-03-18 0001446159poai:ABAndAgentWarrantsPriorToReclassificationMember2020-01-012020-03-31 0001446159poai:ABAndAgentWarrantsMember2021-12-31 0001446159poai:ABAndAgentWarrantsMember2021-01-012021-12-31 0001446159poai:ABAndAgentWarrantsMember2020-12-31 0001446159poai:ABAndAgentWarrantsMember2020-01-012020-12-31 0001446159poai:WarrantsAndAgentWarrantsInConnectionWithMay2020WarrantMember2020-05-08 0001446159poai:WarrantsAndAgentWarrantsInConnectionWithMay2020WarrantMember2020-01-012020-12-31 0001446159poai:AgentWarrantsIssuedInConnectionWithMay2020OfferingMember2021-12-31 0001446159poai:AgentWarrantsIssuedInConnectionWithMay2020OfferingMember2020-12-31 0001446159poai:AgentWarrantsIssuedInConnectionWithMay2020OfferingMember2021-01-012021-12-31 0001446159poai:AgentWarrantsIssuedInConnectionWithMay2020OfferingMember2020-01-012020-12-31 0001446159poai:WarrantsAndAgentWarrantsInConnectionWithJune2020WarrantMember2020-06-30 0001446159poai:WarrantsAndAgentWarrantsInConnectionWithJune2020WarrantMember2020-01-012020-12-31 0001446159poai:AgentWarrantsInConnectionWithJune2020WarrantMember2021-01-012021-12-31 0001446159poai:AgentWarrantsInConnectionWithJune2020WarrantMember2020-01-012020-12-31 0001446159poai:AgentWarrantsInConnectionWithJune2020WarrantMember2021-12-31 0001446159poai:AgentWarrantsInConnectionWithJune2020WarrantMember2020-12-31 0001446159poai:PromissoryNote2019ConversionFeatureMember2019-09-30 0001446159poai:PromissoryNote2019ConversionFeatureAgentWarrantsMember2021-03-01 0001446159poai:PromissoryNote2019ConversionFeatureAgentWarrantsMember2021-01-012021-12-31 0001446159poai:PromissoryNote2019ConversionFeatureAgentWarrantsMember2020-01-012020-12-31 0001446159poai:PromissoryNote2019ConversionFeatureAgentWarrantsMember2020-12-31 00014461592018-12-31 0001446159poai:PromissoryNote2020Member2020-01-012020-12-31 0001446159poai:WarrantsAndAgentWarrantsInConnectionWithMay2020WarrantMember2020-12-31 0001446159poai:WarrantsAndAgentWarrantsInConnectionWithJune2020WarrantMember2020-12-31 0001446159poai:PromissoryNote20202Member2020-01-012020-12-31 00014461592019-01-012019-12-31 0001446159us-gaap:EmployeeStockOptionMember2021-01-012021-12-31 0001446159us-gaap:EmployeeStockOptionMember2020-01-012020-12-31 0001446159us-gaap:WarrantMember2021-01-012021-12-31 0001446159us-gaap:WarrantMember2020-01-012020-12-31 0001446159us-gaap:ConvertibleDebtSecuritiesMember2020-01-012020-12-31 0001446159poai:SeriesBConvertiblePreferredStockMember2021-01-012021-12-31 0001446159poai:SeriesBConvertiblePreferredStockMember2020-01-012020-12-31 0001446159us-gaap:DomesticCountryMember2020-12-31 0001446159us-gaap:StateAndLocalJurisdictionMember2020-12-31 0001446159us-gaap:ForeignCountryMember2020-12-31 0001446159us-gaap:DomesticCountryMember2021-12-31 0001446159us-gaap:StateAndLocalJurisdictionMember2021-12-31 0001446159poai:PatentsAndTrademarksMember2021-12-31 0001446159poai:PatentsAndTrademarksMember2021-01-012021-12-31 0001446159poai:PatentsAndTrademarksMember2020-12-31 0001446159us-gaap:DevelopedTechnologyRightsMember2021-12-31 0001446159us-gaap:DevelopedTechnologyRightsMember2021-01-012021-12-31 0001446159us-gaap:DevelopedTechnologyRightsMember2020-12-31 0001446159us-gaap:CustomerRelationshipsMember2021-12-31 0001446159us-gaap:CustomerRelationshipsMember2021-01-012021-12-31 0001446159us-gaap:CustomerRelationshipsMember2020-12-31 0001446159us-gaap:TradeNamesMember2021-12-31 0001446159us-gaap:TradeNamesMember2021-01-012021-12-31 0001446159poai:TradeNames1Member2021-12-31 0001446159poai:TradeNames1Member2020-12-31 0001446159poai:HelomicsHoldingCorpMember2019-04-04 00014461592020-01-012020-09-30 0001446159poai:MeasurementInputExpectedCashFlowTermMember2020-09-30 0001446159us-gaap:MeasurementInputLongTermRevenueGrowthRateMember2020-09-30 0001446159us-gaap:MeasurementInputDiscountRateMember2020-09-30 0001446159poai:MeasurementInputRiskPremiumMember2020-09-30 00014461592020-10-012020-12-31 0001446159poai:HelomicsHoldingCorpMember2020-01-012020-12-31 0001446159poai:MeasurementInputExpectedCashFlowTermMember2020-12-31 0001446159us-gaap:MeasurementInputLongTermRevenueGrowthRateMember2020-12-31 0001446159us-gaap:MeasurementInputDiscountRateMember2020-12-31 0001446159poai:MeasurementInputRiskPremiumMember2020-12-31 00014461592021-01-012021-09-30 00014461592021-09-30 0001446159poai:MeasurementInputExpectedCashFlowTermMember2021-09-30 0001446159us-gaap:MeasurementInputLongTermRevenueGrowthRateMember2021-09-30 0001446159us-gaap:MeasurementInputDiscountRateMember2021-09-30 0001446159poai:CorporateOfficeMinnesotaMember2021-12-31 utr:sqft 0001446159poai:CorporateOfficeMinnesotaUsedForOfficeSpaceMember2021-12-31 0001446159poai:CorporateOfficeMinnesotaUsedForManufacturingMember2021-12-31 0001446159poai:HelomicsOfficesMember2021-12-31 0001446159poai:HelomicsOfficesLeaseAreaForOfficeSpaceMember2021-12-31 0001446159poai:HelomicsOfficesLeaseAreaForLaboratoryMember2021-12-31 0001446159poai:ZPREDICTAOfficesInSanJoseCaliforniaMember2021-12-31 0001446159poai:SolubleBiodtechOfficesInBirminghamAlabamaMember2021-12-31 0001446159poai:TumorgenesisOfficesInSalemMassachusettsMember2021-12-31 0001446159poai:SkylineMedicalEuropesOfficesLeaseMember2021-12-31 0001446159poai:SkylineMedicalEuropesOfficesLeaseStorageSpaceMember2021-12-31 0001446159poai:SkylineMedicalEuropesOfficesLeaseOfficeSpaceMember2021-12-31 0001446159us-gaap:OfficeEquipmentMember2021-12-31 0001446159us-gaap:OfficeEquipmentMember2020-12-31 0001446159poai:LaboratoryEquipmentMember2021-12-31 0001446159poai:LaboratoryEquipmentMember2020-12-31 0001446159us-gaap:LeaseholdImprovementsMember2021-12-31 0001446159us-gaap:LeaseholdImprovementsMember2020-12-31 0001446159poai:ManufacturingToolingMember2021-12-31 0001446159poai:ManufacturingToolingMember2020-12-31 0001446159poai:DemoEquipmentMember2021-12-31 0001446159poai:DemoEquipmentMember2020-12-31 0001446159poai:OtherFinitelivedIntangibleAssetsMember2021-01-012021-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:SkylineMember2021-01-012021-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:HelomicsSegmentMember2021-01-012021-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:SolubleMember2021-01-012021-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:ZPREDICTAMember2021-01-012021-12-31 0001446159us-gaap:CorporateNonSegmentMember2021-01-012021-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:SkylineMember2021-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:HelomicsSegmentMember2021-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:SolubleMember2021-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:ZPREDICTAMember2021-12-31 0001446159us-gaap:CorporateNonSegmentMember2021-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:SkylineMember2020-01-012020-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:HelomicsSegmentMember2020-01-012020-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:SolubleMember2020-01-012020-12-31 0001446159us-gaap:CorporateNonSegmentMember2020-01-012020-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:SkylineMember2020-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:HelomicsSegmentMember2020-12-31 0001446159us-gaap:OperatingSegmentsMemberpoai:SolubleMember2020-12-31 0001446159us-gaap:CorporateNonSegmentMember2020-12-31 0001446159srt:DirectorMember2019-04-01 0001446159srt:DirectorMember2019-05-01 00014461592018-01-012018-12-31 0001446159us-gaap:SubsequentEventMemberpoai:EquityLinePurchaseAgreementMember2022-01-012022-03-28
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-K

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021.

  

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                    TO

 

COMMISSION FILE NUMBER: 001-36790

 

PREDICTIVE ONCOLOGY INC.

(Exact name of registrant as specified in its charter)

 

Delaware

33-1007393

(State or other jurisdiction

of incorporation or organization)

(IRS Employer

Identification No.)

 

2915 Commers Drive, Suite 900

Eagan, Minnesota 55121

(Address and Zip Code of principal executive offices)

 

(Registrant’s telephone number, including area code): (651) 389-4800

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common stock, $0.01 par value

POAI

NASDAQ Capital Market

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No

 

Indicate by checkmark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.  

 

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☒  

Smaller reporting company 

 

Emerging growth company   

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No ☒

 

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: $85,590,000 as of June 30, 2021, based upon 65,339,695 shares at $1.31 per share as reported on the NASDAQ Capital Market.

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the last practicable date: As of March 24, 2022, the registrant had 65,911,001 shares of common stock, par value $.01 per share outstanding.

 

 

DOCUMENTS INCORPORATED BY REFERENCE

 

 

 

 

 

 

TABLE OF CONTENTS

 

 

Page

PART I

 
   

ITEM 1. BUSINESS

4

   

ITEM 1A. RISK FACTORS

15

   

ITEM 1B. UNRESOLVED STAFF COMMENTS

29

   

ITEM 2. PROPERTIES

29

   

ITEM 3. LEGAL PROCEEDINGS

29

   

ITEM 4. MINE SAFETY DISCLOSURES

29

   

PART II

 
   

ITEM 5. MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

30

   

ITEM 6. SELECTED FINANCIAL DATA

30

   

ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

30

   

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

43

   

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

43

   

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

43

   

ITEM 9A. CONTROLS AND PROCEDURES

43

   

ITEM 9B. OTHER INFORMATION

44

   

PART III

 
   

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

44

   

ITEM 11. EXECUTIVE COMPENSATION

50

   

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

58

   

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

60

   

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

61

   

PART IV

 
   

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

62

   

SIGNATURES

63

 

 

 

 

 

PART I

 

ITEM 1. BUSINESS

 

General

 

References in this annual report on Form 10-K to Predictive, Company, we, us, and our refer to the business of Predictive Oncology Inc. (NASDAQ: POAI) and its wholly-owned subsidiaries.

 

Cautionary Statement Concerning Forward-Looking Statements

 

This Annual Report on Form 10-K contains various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements represent our expectations and beliefs concerning future results or events, based on information available to us on the date of the filing of this Form 10-K, and are subject to various risks and uncertainties. Factors that could cause actual results or events to differ materially from those referenced in the forward-looking statements are listed in Part I, Item 1A. Risk Factors and in Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. We disclaim any intent or obligation to update or revise any of the forward-looking statements, whether in response to new information, unforeseen events, changed circumstances or otherwise, except as required by applicable law.

 

Overview

 

We operate in four primary business areas: first, the application of artificial intelligence (“AI”) in our precision medicine business, to provide AI-driven predictive models of tumor drug response to improve clinical outcomes for patients and to assist pharmaceutical, diagnostic, and biotech industries in the development of new personalized drugs and diagnostics; second, creation and development of tumor-specific 3D cell culture models driving accurate prediction of clinical outcomes; third, contract services and research focused on solubility improvements, stability studies, and protein production, and;  fourth, production of the United States Food and Drug Administration (“FDA”)-cleared STREAMWAY® System for automated, direct-to-drain medical fluid disposal and associated products.

 

We have four reportable segments: Helomics®, zPREDICTA®, SolubleTM and Skyline®. The Helomics segment includes clinical testing and contract research services that include the application of AI. Our zPREDICTA, Inc. (“zPREDICTA”) segment, which was effective upon the closing of the acquisition of zPREDICTA on November 24, 2021, specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. Our Soluble segment provides services using a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. Our Skyline segment consists of the STREAMWAY System product sales, and our TumorGenesis® subsidiary (Research and Development) is included within corporate. Going forward, we have determined that we will focus our resources on the Helomics and zPREDICTA segments and our primary mission statements to accelerate patient-centric drug discovery to improve patient outcomes in cancer treatment, harnessing the power of AI, and to develop tumor-specific 3D cell culture models that provide accurate 3D reconstruction of human tissues representing each cancer disease state.

 

On November 24, 2021, we acquired zPREDICTA in a merger transaction, and at that time we identified zPREDICTA as a reportable segment. zPREDICTA’s business, which involves integration of organ-specific cellular and extracellular elements into 3D cell culture models for in vitro cancer drug testing, represents a unique segment in the Predictive offerings.

 

HELOMICS

 

Our precision medicine business, conducted in our Helomics division, is committed to improving the effectiveness of cancer therapy using our proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

 

4

 

Helomics’ mission is to improve clinical outcomes for patients by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. Our Patient-centric Drug Discovery using Active Learning asset (“PeDAL”™) is a unique technology that combines our proprietary, clinically validated patient tumor cell line assay (“TruTumor”™), a vast knowledgebase of proprietary and public data together (“TumorSpace”™) with active learning - the active learning allowing the efficient exploration of compound drug responses against a large diverse patient “space”. PeDAL offers researchers the opportunity to efficiently and cost-effectively bring patient diversity much earlier in the drug discovery process. PeDAL works by iterative cycles of active-learning powered Learn-Predict-Test to guide the testing of patient-specific compound responses using the TruTumor assay and patient cell lines to build a comprehensive predictive model of patient responses to compounds. This predictive model can then be used to rank compounds by the fraction of patients of certain profiles that respond as well as the set of compounds that provide the best coverage across patients. PeDAL will be used in fee-for-service projects with pharmaceutical companies.

 

Contract Research Organization (CRO) and AI-Driven Business

 

We believe leveraging our unique, historical database of the drug responses of over 150,000 patient tumors to build AI and data-driven multi-omic predictive models of tumor drug response and outcome will provide actionable insights critical to both new drug development and individualizing patient treatment. Through the course of over 15 years of clinical testing of the responses of patient tumors to drugs, Helomics has amassed a huge proprietary knowledgebase of 150,000 patient cases. This data has been rigorously de-identified and aggregated to build a unique, proprietary model of tumor drug response that we call TumorSpace. The TumorSpace model and its data provide a priori knowledge for the machine learning approaches we employ as part of the PeDAL approach.

TumorSpace model provides a significant competitive advantage to our business offerings. PeDAL's unique patient and tumor-centric AI-driven approach can rapidly and cost-effectively screen hundreds of compounds in thousands of tumor cell lines, and gain valuable information about off-target effects and deliver:

 

A ranked list of drug candidates by responsiveness
Sets of drug candidates that provide maximum patient coverage
Biomarker profiles of patients that respond to specific drug candidates

 

PeDAL also can deliver drug candidates targeted at a specific patient profile as early as the hit-to-lead stage of discovery, significantly increasing the chance of clinical success, leading to a dramatic improvement in both the success, time, and cost of your oncology discovery programs. The AI-driven models will also provide clinical decision support to help oncologists individualize treatment.

 

Our CRO/AI business leverages our core competence in profiling the drug response of patient tumors. Our large knowledgebase of tumor drug response and other data, together with proven AI, has created a unique capability for oncology drug discovery that allows for the highly efficient screening of drug responses from thousands of diverse, well-characterized patient primary tumor cell lines. This novel disruptive patient-centric approach is ideally suited to the early part of drug discovery (especially hit-to-lead, lead optimization, and pre-clinical), resulting in better prioritization of compounds and better coverage of patient diversity. This will dramatically improve the chances of successfully translating discoveries, resulting in lowered costs, shortened timelines, and most importantly enhanced “speed-to-patient” for new therapies.

 

Our CRO services business applies PeDAL to address a range of needs from discovery through clinical and translational research, to clinical trials and diagnostic development and validation as noted below:

 

Research
 

Biomarker discovery

 

Drug discovery

 

Drug-repurposing

     
Development
 

Patient enrichment & selection for trials

 

Clinical trial optimization

 

Adaptive trials

 

5

 

Clinical Decision Support
 

Patient stratification

 

Treatment selection

 

We believe this market segment has significant growth potential and we believe we are differentiated from traditional CRO’s and other precision medicine and AI companies through these unique assets:

 

 

Clinically validated TruTumor platform;

 

TumorSpace model of over 150,000 tumor cases;

 

Experienced AI team and AI/Core® platform;

 

Ability to access outcome data going back over ten years for over 120,000 of the tumor cases in our database.

 

Industry and Market Background and Analysis Precision Medicine Business

 

Precision medicine is an emerging approach for disease treatment and prevention that considers individual variability in genes, disease, environment, and lifestyle for each case to develop effective therapies. This approach allows doctors and researchers to predict more accurately which treatment, dose, and therapeutic regimen could provide the best possible outcome.

 

Precision medicine, precisely targeting drugs based on the genomic profile of the patient, has become the aspiration for cancer therapy. Over the past several decades, researchers have identified molecular patterns that are useful in defining the prognosis of a given cancer, determining the appropriate treatments, and designing targeted treatments to address specific molecular alterations. The objective of this precision oncology is to develop treatments tailored to the genetic changes in each person’s cancer, intended to improve the effectiveness of the therapeutic regimen, and minimize the treatment’s effects on healthy cells. However, for a majority of patients the reality is that while many mutations in the patient’s tumor can be identified most are not actionable with current protocols, due to a lack of research regarding which mutations in a tumor confer a sensitivity to a particular drug. As a result, the impact of targeted therapies is low, and uptake in clinical practice is inconsistent.

 

There is now a growing realization that genomics alone will not be enough to achieve the promise of personalized therapeutics, especially for cancer. A multi-omic approach (e.g., assessing the genome, transcriptome, epigenome, proteome, responseome, and microbiome) provides researchers and clinicians the comprehensive information necessary for new drug development and individualized therapy. Comparatively, the multi-omic approach provides a three-dimensional, 360-degree view of the cancer, while genomics alone is just a flat, one-dimensional view. However, multi-omic data is difficult to access quickly as it is both costly and time consuming to initiate prospective data collection, and few comprehensive, multi-omic datasets exist, especially specific to cancer. Our Helomics TumorSpace database addresses this need.

 

Clinical Testing

 

Via our Helomics subsidiary, we offer a group of clinically relevant, cancer-related tumor profiling and biomarker tests for gynecological cancers that determine how likely the patient is to respond to various types of chemotherapy and which therapies might be indicated by relevant tumor biomarkers.

 

Clinic diagnostic testing is comprised of our Tumor Drug Response Testing (ChemoFx) and Genomic Profiling (BioSpeciFx) tests. The Tumor Drug Response Testing test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the Genomic Profiling test evaluates the expression and/or status of a particular gene related to a patient’s tumor specimen. Our proprietary TruTumor platform provides us with the ability to work with actual live tumor cells to study the unique biology of the patient’s tumor in order to understand how the patient responds to treatment.

 

Testing involves obtaining tumor tissue during biopsy or surgery which is then sent to our Clinical Laboratory Improvement Amendments (“CLIA”) certified laboratory using a special collection kit. Tumor Drug Response Testing is a fresh tissue platform that uses the patient’s own live tumor cells to help physicians identify effective treatment options for each gynecologic cancer patient.

 

6

 

Genomic Profiling offers a select group of clinically relevant protein expression and genetic mutation tests associated with drug response and disease prognosis. Physicians can select biomarkers for testing from carefully chosen panels of relevant tests, intuitively organized by cancer pathway and tumor type. Results for these tests are presented in a clear, easy to understand format, including summaries of the clinical relevance of each marker.

 

Business Strategy for Precision Medicine Business

 

We are a data and AI-driven discovery services company that provides AI-driven predictive models of tumor drug response to improve clinical outcomes for patients by leveraging our two primary unique assets:

 

 

TruTumor - a clinically validated tumor-profiling platform that can generate drug response profiles and other multi-omic data. Over $200 million has been invested in this platform by us and previous owners and was clinically validated in ovarian cancer.

     
 

TumorSpace model contains data on the drug response profiles across 131 cancer types over 10+ years of clinical testing.

 

Over 38,000 of the more than 150,000 clinically validated cases in our TumorSpace database are specific to ovarian cancer. The data in TumorSpace is highly differentiated, having both drug response data, biomarkers, and access to historical outcome data from those patient samples. We intend to generate additional data (genomics and transcriptomics) from these tumor samples to deliver a multi-omic approach to the pharmaceutical industry.

 

Through our Helomics subsidiary, we will utilize both this historical data and the TumorSpace platform to build AI-driven predictive models of tumor drug response and outcome. During 2022, we will commercialize these AI-driven predictive models in revenue generating service projects with pharmaceutical, biotech, and diagnostic companies.

 

A key part of our commercialization strategy is the understanding that our AI-driven models of tumor drug response serve a key unmet need of pharmaceutical, diagnostic, and biotech industries for actionable multi-omic insights on cancer. In collaboration with these companies, using the predictive models, we will accelerate the search for more individualized and effective cancer treatments, through revenue generating projects in biomarker discovery, drug screening, drug repurposing, and clinical trials.

 

Our commercial strategy has identified a portfolio of revenue generating project types that leverage the predictive models, our AI expertise, PeDAL tumor profiling, and CLIA laboratory to provide custom solutions utilizing our full array of assets and expertise.

 

The Cancer Quest 2020 initiative focused initially on ovarian cancer, which is where we have the most expertise, samples, data, and access to outcomes. We are expanding the initiative to include cancers of the lung, breast, colon, and prostate, and will actively seek partners to assist in that effort.

 

We recently completed our product validation for Discovery 21in January 2022, the proof of concept for PeDAL, which incorporates CoRE™, our active machine learning program, with tumor profile data and human tumor samples, to efficiently determine the most effective drug treatment for a specific cancer type. With each iteration of PeDAL, the program learns, predicts, and then directs the most informative wet lab experimentation, while building the predictive model.

 

Discovery 21 is a predictive model, built in an efficient manner using PeDAL. The model revealed drug response patterns that provide insight into the treatment of ovarian cancer. The validation results demonstrated the accuracy of the model that predicted drug response. Within the clinical sector, we will also be able to utilize similar predictive models (once validated) for new clinical decision support tools for individualizing therapy for patients with cancer.

 

7

 

These clinical decision support tools are on a longer revenue horizon than the fee-for-service research projects with pharmaceutical companies but, importantly, will provide a steady stream of additional data generation to refine the predictive models for both clinical and research applications.

 

zPREDICTA

 

zPREDICTA develops tumor-specific in vitro models for oncology drug discovery and research by biopharmaceutical companies and other clients and partners. zPREDICTA’s 3D product models accelerate the drug development process for its clients and partners by leveraging the expertise in carcinogenesis, metastasis and the tumor microenvironment. It develops complex in vitro models that recapitulate the physiological environment of human tissue.

 

From target discovery and lead optimization to preclinical evaluation of efficacy and toxicity, the objective is to develop the tools necessary to accurately identify compounds that will have the highest probability of improving human health. Product offerings include preclinical testing services based on our proprietary models directly to clients in the biopharmaceutical industry.

 

zPREDICTA has expertise in creating human, disease-specific tissue microenvironments for testing drug efficacy and safety. Unlike other platforms, the patented 3D models utilize proprietary organ-specific extracellular matrix formulations that match the in vivo milieu of the organ of interest. These models reconstruct both cellular and extracellular compartments of each tissue, which is especially essential for testing of immuno-oncology agents.

 

zPREDICTA technology demonstrates high clinical relevance, enabling its pharma clients to manage pipeline attrition more efficiently by identifying drugs that are effective in patients, from the hundreds, and often thousands, of compounds in development. The tumor-specific models are used a number of biopharmaceutical companies to evaluate the efficacy and toxicity of their therapeutic pipelines. Our models replicate the extracellular matrix (“ECM”) of individual organs and disease-specific soluble microenvironment mimicking the biology of human disease, and as such, demonstrate high correlation with clinical response.

 

The zPREDICTA 3D tumor-specific models incorporate tissue-specific extracellular matrices and tumor-specific medium supplements allowing for a true reconstruction of tumor microenvironment. Our approach is compatible with multiple classes of immuno-oncology agents from naked antibodies and antibody-drug conjugates, to bi- and tri-specific compounds, and CAR-T cells. The organ-specific disease models provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response.

 

Our platform incorporates both cellular and extracellular elements of tissue microenvironment in an organ- and disease-specific manner.

 

Extracellular components

Cell-cell interactions

●         extracellular matrix

●         tumor-tumor interactions

   

●         soluble factors (cytokines, etc.)

●         tumor-stroma interactions

 

Our platform is designed to evaluate drug candidates and drug combinations within the native microenvironment of human tissues. Our technology is a patient-derived 3D culture platform that recreates the complex human organ microenvironment thereby preserving the critical interactions between a tumor and its surroundings. Our platform supports long-term survival and proliferation of malignant and non-malignant cellular components of tissues. This includes tumor cells, stroma, and immune components. Anticancer compounds tested in our models exhibit high correlation with clinical response when comparing treatment outcomes in the clinic with cellular behavior in response to the therapeutic regimen. Our organ-specific technology is compatible with multiple drug classes, including small molecules, antibodies, antibody-drug conjugates, immunomodulatory agents, CAR-T cells, etc. Our platform is fully customizable to the tumor and tissue of interest. It is compatible with multiple cell types, drug classes, and downstream analysis methods.

 

8

 

Applications include providing efficacy screening of anticancer compounds, evaluation of mechanisms of drug resistance, identification of new drug combinations, rescue of failed drug candidates, assessment of off-target toxicity, target discovery and biomarker discovery.

 

SOLUBLE BIOTECH

 

Our subsidiary, Soluble Biotech Inc. (“Soluble”), focuses on contract services and research for biopharmaceutical company clients and academic collaborators, focused on solubility improvements, stability studies, and protein production. Specifically, Soluble provides optimized FDA-approved formulations for vaccines, antibodies, and other protein therapeutics in a faster and lower cost basis to its customers. In addition, Soluble enables protein degradation studies, which based on current projections, potentially substantial line of business for the Company.

 

The primary assets of Soluble are our automated High Throughput Self-Interaction Chromatography (HSC™). HSC is a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens on excipients previously approved by the FDA for protein formulations. Our technology measures second virial coefficient (B22 value) of protein-protein interactions to identify excipients that promote protein solubility in solutions. The data generated from HSC screens are analyzed by a proprietary predictive algorithm to identify the optimal combination(s) of buffers, pH, and excipients, resulting in increased solubility and physical stability of proteins. Several of our clients have seen ten-fold and hundred-fold increases in their protein’s solubility while maintaining physical stability. For biopharmaceutical clients this means faster development times and quicker progression of molecules into the clinic. For academic collaborators, this means further progression of biochemical & biology studies necessary to advance fundamental research in areas of unmet medical need.

 

In addition, Soluble provides comprehensive protein stability analysis. Analysis via time-dependent shelf-life studies and forced degradation studies designed to quickly determine which of the previously FDA approved additives that will improve the solubility and stability of proteins in solutions. Services include pre-formulation development, stability assessment, and biophysical characterization which evaluate variables including pH, temperature, humidity, light, oxidizing agents, and mechanical stress to determine the most promising additives, formulation of B22 values and confirmation on conformation stability. We provide clients with a list of the most promising additives from a set of over 40 different additives that can increase the solubility and stability of protein formulations.

 

Soluble also offers protein solubility kits that allow rapid identification of soluble formulations. We provide four different kits to fulfill customer solubility requirements. The kits are in 96-well format and provide the tools and methods to compare relative solubility across 88 common formulations (with 8 controls). Soluble kits utilize a simple mix and spin protocol that quickly evaluates aggregation behavior as a function of pH, salt, and additives costing significantly less than if manually determined. In addition, we provide innovative technologies for bacterial detection and removal in therapeutic proteins that continue to be a significant issue in the pharmaceutical field.

 

In addition, Soluble supplies proprietary technologies for bacterial endotoxin detection and removal. Endotoxin is an inherent byproduct of bacterial expression of therapeutic proteins. However, therapeutic proteins are required to have extremely low endotoxin levels. Soluble provides a product to remove endotoxin that works through multiple molecular interactions for efficient removal over a wide range of buffer conditions with minimal product loss. The detection of endotoxin can also be adversely affected by the protein therapeutic itself. To address this, Soluble provides sample treatment kits to minimize detection interference while using standard detection assays.

 

SKYLINE MEDICAL The STREAMWAY System

 

Sold through our subsidiary, Skyline Medical Inc. (“Skyline Medical”), the STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled fluid canisters present both an exposure risk and potential liability. Skyline Medical’s STREAMWAY System fully automates the collection, measurement, and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers; 2) improve compliance with the Occupational Safety and Health Administration (“OSHA”) and other regulatory agency safety guidelines; 3) improve efficiency in the operating room and radiology and endoscopy departments, thereby leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills each year in the United States. We continue to operate the Skyline Medical business by continually improving our strategic opportunities, while focusing our resources on our precision medicine business.

 

9

 

Industry and Market Background and Analysis - Infectious and Biohazardous Waste Management

 

There has long been recognition of the collective potential for ill effects to healthcare workers from exposure to infectious/biohazardous materials. Federal and state regulatory agencies have issued mandatory guidelines for the control of such materials, and in particular, bloodborne pathogens. OSHA’s Bloodborne Pathogens Standard (29 CFR 1910.1030) requires employers to adopt engineering and work practice controls that would eliminate or minimize employee exposure from hazards associated with bloodborne pathogens. In 2001, in response to the Needlestick Safety and Prevention Act, OSHA revised the Bloodborne Pathogens Standard. The revised standard clarifies and emphasizes the need for employers to select safer needle devices and to involve employees in identifying and choosing these devices. The revised standard also calls for the use of “automated controls” as it pertains to the minimization of healthcare exposure to bloodborne pathogens.

 

Most surgical procedures produce potentially infectious materials that must be disposed with the lowest possible risk of cross-contamination to healthcare workers. Current standards of care allow for these fluids to be retained in canisters and located in the operating room where they can be monitored throughout the surgical procedure. Once the procedure is complete these canisters and their contents are disposed using a variety of methods, all of which include manual handling and result in a heightened risk to healthcare workers for exposure to their contents. Canisters are the most prevalent means of collecting and disposing of infectious fluids in hospitals today. Traditional, non-powered canisters and related suction and fluid disposable products are exempt and do not require FDA clearance. 

 

We believe that our virtually hands free direct-to-drain technology (1) significantly reduces the risk of healthcare worker exposure to these infectious fluids by replacing canisters, (2) further reduces the risk of worker exposure when compared to powered canister technology that requires transport to and from the operating room, (3) reduces the cost per procedure for handling these fluids, and (4) enhances the surgical team’s ability to collect data to accurately assess the patient’s status during and after procedures. In addition to the traditional canister method of waste fluid disposal, several other powered medical devices have been developed that address some of the deficiencies described above. Most of these competing products continue to utilize some variation on the existing canister technology, and while not directly addressing the canister, most have been successful in eliminating the need for an expensive gel and its associated handling and disposal costs.  Our existing competitors with products already on the market have a clear competitive advantage over us in terms of brand recognition and market exposure. In addition, many of our competitors have extensive marketing and development budgets that could overpower an emerging growth company like ours.

 

We expect the hospital surgery market to continue to increase due to population growth, the aging of the population, and expansion of surgical procedures to new areas (for example, use of the endoscope) which requires more fluid management and new medical technology.

 

STREAMWAY System Product Sales

 

Our Skyline Medical division consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. We manufacture an environmentally conscious system for the collection and disposal of infectious fluids resulting from surgical and other medical procedures. We have been granted patents for the STREAMWAY System in the United States, Canada, and Europe. We distribute our products to medical facilities where bodily and irrigation fluids produced during medical procedures must be contained, measured, documented, and disposed. Our products minimize the exposure potential to the healthcare workers who handle such fluids.

 

The STREAMWAY System is a wall-mounted fully automated system that disposes of an unlimited amount of suction fluid providing uninterrupted performance for physicians while virtually eliminating healthcare workers’ exposure to potentially infectious fluids collected during surgical and other patient procedures. We also manufacture and sell two disposable products required for the operation of the STREAMWAY System: a bifurcated dual port procedure filter with tissue trap and a single use bottle of cleaning solution. Both items are utilized on a single procedure basis and must be discarded after use. The STREAMWAY disposables are a critical component of our business model. Recurring revenues from the sale of the disposables are expected to be significantly higher over time than the revenues from the initial sale of the unit. We have exclusive distribution rights to the disposable solution.

 

10

 

TUMORGENESIS

 

Our subsidiary TumorGenesis is our research and development arm for Helomics and zPREDICTA. TumorGenesis also specializes in media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. With this tool, researchers are able to expand and study cancer cell types inherent in blood tumors and organ systems of all mammals, including humans.

 

Competition and Competitive Advantages

 

Precision Medicine Business. We presently have clinical information, including tumor drug response data and an in-house bioinformatics AI platform. Cancer treatments require at least 5 years of testing to see progression-free survival rates. While competitors must wait for this data, we can leverage that data today. Other companies within our market segment are spending significant investment dollars to generate this data which they cannot leverage until the future. We can leverage the data today by sequencing the tumors and gathering the outcome data which is measured in months instead of years. In addition, the following points detail the key differentiators in our model building approach.

 

AI Models are built with real world data on how patient tumors responded to drugs, together with clinical outcome (progression-free survival/overall survival).

   

We believe this patient-centric, highly standardized, and curated, multi-omic tumor model offers a better chance of generating serviceable predictive models of drug-response and outcomes than competitive approaches in the market today. The information embodied in the AI-driven predictive model provides insights into each tumor’s response to different therapeutic options, resulting in the ability to provide actionable insights critical to both new drug development and individualizing patient treatment.

 

zPREDICTA. Our next-generation technology based on extensive research of the human tumor microenvironment creating accurate reconstruction of the organ-specific 3D tissue microenvironment enabling evaluation of therapeutic agents under conditions mimicking human physiology. The main competitive advantage of zPREDICTA’s technology is the tumor-specific nature of its systems. 3D models replicate tissue heterogeneity and provides long-term maintenance of primary human cells, organoids, and cell lines under the native conditions of human disease. The 3D models are formulated to mimic the tissue and disease of interest instead of pursuing a one-size-fits-all approach taken by other companies. Services provide reliable prediction of clinical outcomes based on accurate reconstruction of cellular and extracellular compartments of human tissues.

 

Soluble Biotech. HSC Technology is a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens on FDA approved excipients for protein formulations. The HSC Instrument and its technology has been validated over the past twelve years via industry and academic collaborations. The data generated from HSC screens are analyzed by a proprietary predictive algorithm to identify the optimal combination(s) of buffers, pH, and excipients, resulting in increased solubility and physical stability of proteins. Several of our clients have seen ten-fold and hundred-fold increases in their protein’s solubility while maintaining physical stability. For biopharmaceutical clients this means faster development times and quicker progression of molecules into the clinic.

 

Skyline Medical. We believe that the STREAMWAY System is unique to the industry in that it not only allows continuous suction but also provides for unlimited capacity, eliminating the need to interrupt a procedure to change canisters. To our knowledge, the STREAMWAY System is the only known fully automated direct‐to‐drain system that is wall‐mounted and able to collect, measure, and dispose of an unlimited amount of waste fluid without interruption.

 

11

 

Suppliers

 

We buy our raw materials from several suppliers and, except as set forth below, the loss of any one supplier would not materially adversely affect our business. We rely on sole suppliers for certain materials used to perform our molecular diagnostic tests. We also purchase reagents used in our molecular diagnostic tests from sole-source suppliers. While we have developed alternate sourcing strategies for these materials and vendors, we cannot be certain that these strategies will be effective or that the alternative sources will be available in a timely manner. If our current suppliers can no longer provide us with the materials, we need to perform molecular diagnostic tests, if the materials do not meet our quality specifications, or if we cannot obtain acceptable substitute materials, there could be an interruption in molecular diagnostic test processing. In the event of the loss of these suppliers, we could experience delays and interruptions that might adversely affect the financial performance of our business.

 

We also have single suppliers for the manufacturing of certain of our Skyline Medical products. Alternative suppliers are available in the market; however, we could experience delays and interruptions that might adversely affect the financial performance of our business including time for machine tooling specific to our products.

 

We have existing and good relationships with our service vendors.

 

Research and Development (R&D)

 

We spent $315,850 and $372,710 in 2021 and 2020, respectively, on R&D. 

 

Intellectual Property

 

We believe that to maintain a competitive advantage in the marketplace, we must develop and maintain protection of the proprietary aspects of our technology. We rely on a combination of patent, trade secret intellectual property rights, and other measures to protect our intellectual property to develop and maintain our competitive position. We seek to protect our trade secrets and proprietary know-how, in part, with confidentiality agreements with employees, although we cannot be certain that the agreements will not be breached, or that we will have adequate remedies if a breach were to occur.

 

zPREDICTA. Our technology is a patient-derived 3D culture platform that recreates the complex human organ microenvironment thereby preserving the critical interactions between a tumor and its surroundings. Our models replicate the extracellular matrix of individual organs and disease-specific soluble microenvironment mimicking the biology of human disease, and as such, demonstrate high correlation with clinical response. Patents include US10,501,717, US11,124,756 and pending application US16/321,277.

 

Skyline Medical. In general, our patents are directed to a system and method for collecting waste fluid from a surgical procedure while ensuring there is no interruption of suction during the surgical procedure and no limit on the volume of waste fluid that can be collected. We hold the following granted patents in the United States, and a pending application in the United States on our earlier STREAMWAY System models: US7469727, US8123731, and US Publication No. US20090216205 (collectively, the “Patents”). The Patents will begin to expire on August 8, 2023.

 

On January 25, 2014, we filed a non-provisional Patent Cooperation Treaty (“PCT”) Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed on January 25, 2013. The PCT allows an applicant to file a single patent application to seek patent protection for an invention simultaneously in each of the 148-member countries of the PCT, including the United States.

The United States Patent Office has assigned application #14/763,459 to our previously filed PCT application.

 

As of November 22, 2017, we were informed that the European Patent Office allowed all our claims for application #14743665.3-1651 and on as of July 11, 2018, we were informed that the European Patent #EP2948200 was granted and published validating in the following countries: Belgium, Germany, Spain, France, United Kingdom, Ireland, Italy, Netherlands, Norway, Poland, and Sweden. Our PCT patent application is for an enhanced model of the surgical fluid waste management system. We utilize this enhanced technology in the updated version of the STREAMWAY System unit we began selling in 2014.

 

12

 

Government Regulation

 

Our businesses are subject to or impacted by extensive and frequently changing laws and regulations in the United States (at both the federal and state levels) and the other jurisdictions in which we conduct business, including some specific to our business, some specific to our industry, and others relating to conducting business generally (e.g., U.S. Foreign Corrupt Practices Act). We also are subject to inspections and audits by governmental agencies. The table below highlights key regulatory schemes applicable to our businesses:

 

CLIA and State Clinical Laboratory Licensing

CLIA regulates the operations of virtually all clinical laboratories, requiring that they be certified by the federal government and that they comply with various technical, operational, personnel, and quality requirements intended to ensure that the services provided are accurate, reliable, and timely.

 

State laws may require additional personnel qualifications or licenses, quality control, record maintenance, proficiency testing, or detailed review of our scientific method validations and technical procedures for certain tests.

 

Violations of these laws and regulations may result in monetary fines, criminal and civil penalties and/or suspension or exclusion from participation in Medicare, Medicaid, and other federal or state healthcare programs.

Medicare and Medicaid; Fraud and Abuse

Diagnostic testing services provided under Medicare and Medicaid programs are subject to complex, evolving, stringent, and frequently ambiguous federal and state laws, and regulations, including those relating to billing, coverage, and reimbursement.

 

Anti-kickback laws and regulations prohibit making payments or furnishing other benefits to influence the referral of tests billed to Medicare, Medicaid, or certain other federal or state healthcare programs.

In addition, federal and state anti-self-referral laws generally prohibit Medicare and Medicaid payments for clinical tests referred by physicians who have an ownership or investment interest in, or a compensation arrangement with, the testing laboratory, unless specific exceptions are met.

 

Federal substance abuse legislation enacted in 2018 contains anti-kickback provisions that are, by their terms, applicable to laboratory testing paid for by all payers. Upon full review of the legislation, we were in compliance at that time and continue to maintain compliance. We monitor regularly and reflect this in our annual compliance report.

 

Some states have similar laws that are not limited in applicability to only Medicare and Medicaid referrals and could also affect tests that are paid for by health plans and other non-governmental payers.

Violations of these laws and regulations may result in monetary fines, criminal and civil penalties and/or suspension or exclusion from participation in Medicare, Medicaid, and other federal or state healthcare programs.

FDA

The FDA has potential regulatory responsibility over, among other areas, instruments, software, test kits, reagents and other devices used by clinical laboratories to perform diagnostic testing in the United States. The FDA may assert regulatory oversight over these areas, and legislative proposals addressing FDA oversight of laboratory developed tests have been introduced in the past and may be enacted in the future. See “Item 1A. Risk Factors” for a discussion of the possible impact of such regulatory or legislative developments.

 

13

 

Environmental, Health and Safety

We are subject to laws and regulations related to the protection of the environment, the health and safety of employees, and the handling, transportation, and disposal of medical specimens, infectious and hazardous waste, radioactive materials, various aspects of pertinent technologies and methods of protection.

 

  Several organizations maintain oversight function including:
    OSHA (Occupational Safety and Health Administration)
    EPA (Environmental Protection Agency)
    DOT (Department of Transportation)
    USPS (US Postal Service)
    US Public Health Service
    JCAHO (Joint Commission on Accreditation of Healthcare Organizations)
    NFPA (National Fire Protection Association)
    AIA (American Institute of Architects)
    AORN (Association of Operating Room Nurses)

Privacy and Security of Health and Personal Information

We are subject to laws and regulations regarding protecting the security and privacy of certain healthcare and personal information, including: (1) the federal Health Insurance Portability and Accountability Act and the regulations thereunder, which establish (a) a complex regulatory framework including requirements for safeguarding protected health information and (b) comprehensive federal standards regarding the uses and disclosures of protected health information; (2) state laws; and (3) the European Union's General Data Protection Regulation.

 

A healthcare provider may be subject to penalties for non-compliance and may be required to notify individuals or state, federal, or county governments if the provider discovers certain breaches of personal information or protected health information.

 

To date, no regulatory agency has established exclusive jurisdiction over the area of biohazardous and infectious waste in healthcare facilities.

 

FDA Clearance of STREAMWAY System under Section 510(k)

 

The FDA Center for Devices and Radiological Health requires 510(k) submitters to provide information that compares its new device to a marketed device of a similar type, in order to determine whether the device is substantially equivalent.

 

We filed the 510(k) submission for clearance of the STREAMWAY System device on March 14, 2009 and received written confirmation on April 1, 2009 that our 510(k) has been cleared by the FDA.

 

Following this 510(k) clearance by the FDA, we continue to be subject to the normal ongoing audits and reviews by the FDA and other governing agencies. These audits and reviews are standard and typical in the medical device industry, and we do not anticipate being affected by any extraordinary guidelines or regulations.

 

Our subsidiary, Skyline Medical has successfully passed FDA audits in the past, with no observations or 483 warning letters issued.

 

Application for Electrical Safety Testing and Certification for STREAMWAY System

 

We sought and achieved testing and certification to the IEC 60606-1 and IEC 60606-1-2, two internationally recognized standards.

 

The 60601-1 3rd edition certification for our STREAMWAY System is valid and enables us to continue to market and sell our product domestically and internationally.

 

We have contracted with TUV, a nationally recognized testing laboratory-NRTL, to certify our STREAMWAY System to the new 60601-1 3rd Edition in late 2016. We attained certification to the new standard, and then submitted it to our Notified Body (BSI) for recommendation for our CE Mark, which we received in June 2017, allowing us to sell products outside of the United States.

 

14

 

Effective November 21, 2016, we received a Medical Device Establishment License to sell the STREAMWAY System and related disposables in Canada.

 

ISO Certification

 

Our subsidiary, Skyline Medical, hired BSI (British Standards Institute) to be its Notified Body and to perform audits to ISO 13485:2003 Standards. On June 1, 2016, we successfully passed the audit of our Quality Management System and received our Certificate of Registration for ISO 13485:2016. Our certificate number is FM 649810.

 

Employees

 

We have 30 full-time employees and 2 part-time employees as of December 31, 2021.

 

Executive Offices

 

Our principal executive offices are located at 2915 Commers Drive; Suite 900; Eagan, Minnesota 55121 and our telephone number is (651) 389-4800.

 

Corporate History

 

We were originally incorporated on April 23, 2002 and reincorporated in Delaware in 2013. We changed our name from Skyline Medical Inc. to Precision Therapeutics Inc. on February 1, 2018 and to Predictive Oncology Inc. on June 13, 2019.

 

Available Information

 

Our website address is http://www.predictive-oncology.com. Information contained on our website is not incorporated by reference into this Annual Report on Form 10-K unless expressly noted.

 

We file reports with the Securities and Exchange Commission (“SEC”), which we make available on our website free of charge at http://investors.predictive-oncology.com/financial-information These reports include Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, each of which is provided on our website as soon as reasonably practicable after we electronically file such materials with, or furnish them to, the SEC. We also make, or will make, available through our website other reports filed with or furnished to the SEC under the Securities Exchange Act of 1934, as amended, including our proxy statements and reports filed by officers and directors under Section 16(a) of that Act. You can also read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, DC 20549. You can obtain additional information about the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains a website (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.

 

You can obtain copies of exhibits to our filings electronically at the SEC’s website at www.sec.gov or by mail from the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549 at prescribed rates. The exhibits are also available as part of the Annual Report on Form 10-K for the year ended December 31, 2021, which is available on our corporate website.

 

ITEM 1A. RISK FACTORS.

 

You should carefully consider the risks described below before making an investment decision. Our business could be harmed by any of these risks. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. The risks described below are not the only ones that we may face. Additional risks that are not currently known to us or that we currently consider immaterial may also impair our business, financial condition or results of operations. In assessing these risks, you should also refer to the other information contained in this Form 10-K, including our financial statements and related notes.

 

15

 

Risk Factors Relating to Our Business

 

Our limited operating history with respect to our precision medicine services makes evaluation of our business difficult. 

 

Our precision medicine services were launched with the initial investment in Helomics during the first quarter of 2018 and have not generated significant revenue to date. Our ability to implement a successful business plan with respect to precision medicine remains unproven and no assurance can be given that we will ever generate sufficient revenues to sustain our business. We have a limited operating history which makes it difficult to evaluate our performance. Our prospects should be considered in light of these risks, and the expenses, technical obstacles, difficulties, market penetration rate, and delays frequently encountered in connection with the development of new businesses. These factors include uncertainty as to whether we will be able to: 

 

 

Succeed in uncertain markets;

 

Respond effectively to competitive pressures;

 

Successfully address intellectual property issues of others;

 

Protect and expand our intellectual property rights; and

 

Continue to develop and upgrade our products.

 

In connection with developing our CRO business, we have committed and will continue to commit significant capital to investments in early-stage companies, all of which may be lost, and which may require us to raise significant additional capital, and our entering into new lines of business will result in significant diversion of management resources, all of which may result in failure of our business.

 

We have committed significant capital and management resources to developing our CRO business and other new business areas, and we intend to continue to devote significant capital and management resources to new businesses. Therefore, we could invest significant capital in business enterprises with no certainty when or whether we will realize a return on these investments. Investments using cash will deplete our capital resources, meaning we will be required to raise significant amounts of new capital. There is no assurance that we will be successful in raising sufficient capital, and the terms of any such financing will be dilutive to our stockholders. We may also acquire technologies or companies by issuing stock or other equity securities rather than, or in addition to, payment of cash, which may have the result of diluting our stockholders’ investments. Further, the energy and resources of our officers and personnel may be substantially diverted to new lines of business, which are unproven. If these businesses are unsuccessful or require too great of a financial investment to be profitable, our business may fail.

 

We rely on sole suppliers for some of the materials used in our molecular diagnostic tests, and we may not be able to find replacements or transition to alternative suppliers in a timely manner.

 

We rely on sole suppliers for certain materials used to perform our molecular diagnostic tests. We also purchase reagents used in our molecular diagnostic tests from sole-source suppliers. While we have developed alternate sourcing strategies for these materials and vendors, we cannot be certain whether these strategies will be effective, or the alternative sources will be available in a timely manner. If these suppliers can no longer provide us with the materials needed to perform our molecular diagnostic tests, if the materials do not meet required quality specifications, or if we cannot obtain acceptable substitute materials, an interruption in molecular diagnostic test processing could occur. Any such interruption may directly impact our revenue and cause us to incur higher costs.

 

 

16

 

If we are sued for product liability or errors and omissions liability, we could face substantial liabilities that exceed our resources.

 

The marketing, sale, and use of our molecular diagnostic tests could lead to product liability claims if someone were to allege that the molecular diagnostic test failed to perform as it was designed. We may also be subject to liability for errors in the results we provide to physicians or for a misunderstanding of, or inappropriate reliance upon, the information we provide. A product liability or errors and omissions liability claim could result in substantial damages and be costly and time consuming for us to defend. Although we maintain product liability and errors and omissions insurance, we cannot be certain that our insurance would fully protect us from the financial impact of defending against these types of claims or any judgments, fines, or settlement costs arising out of such claims. Any product liability or errors and omissions liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could cause injury to our reputation or cause us to suspend sales of our products and solutions. The occurrence of any of these events could have a material adverse effect on our business, financial condition, and results of operations.

 

If our R&D and commercialization efforts for our TruTumor and PeDAL platforms take longer than expected, the commercial revenues from the service offerings that use these platforms could also be delayed.

 

Our CRO business offers various services to pharma, diagnostics, and biotech companies. These services use our TruTumor tumor platform and our PeDAL platform. These platforms are the subject of active R&D to further improve them for commercial use in order to help our clients in their drug discovery, biomarker, and clinical trial activities. We could face delays in this R&D, for example:

 

 

we may not be able to secure access to and approval to use clinical data from academic hospital partners in a timely manner;

 

clinical testing volume (number of specimens coming to us for testing) may not grow sufficiently to drive additional data generation as well as further development of the TruTumor platform;

 

patient consent to use the patient’s data and tumor material for R&D may not be sufficient to support R&D; and

 

we may not be able to attract and retain the appropriately qualified staff to perform the necessary R&D.

 

We have a limited operating history with the CRO business particularly services using our PeDAL, platform as these are new to the market, which makes it difficult to forecast our future revenues. While we are committed to the buildout of the CRO services for the long term, we cannot predict at this time, with any certainty, the future viability of either business unit.

 

We face significant competition in the surgical fluid waste management industry, including competition from companies with considerably greater resources than ours, and if we are unable to compete effectively with these companies, our market share may decline, and our business could be harmed.

 

The surgical fluid waste management industry is highly competitive with numerous competitors ranging from well-established manufacturers to innovative start-ups. Several of our competitors have significantly greater financial, technological, engineering, manufacturing, marketing, and distribution resources than we do. Their greater capabilities in these areas may enable them to compete more effectively on the basis of price and production and more quickly develop new products and technologies.

 

Companies with significantly greater resources than ours may be able to reverse engineer our products and/or circumvent our intellectual property position. Such action, if successful, would greatly reduce our competitive advantage in the marketplace.

 

We believe our ability to compete successfully with our STREAMWAY System depends on a number of factors, including, without limitation, our technical innovations of unlimited suction and unlimited capacity capabilities, our innovative and advanced research and development capabilities, strength of our intellectual property rights, sales and distribution channels, and advanced manufacturing capabilities. We plan to employ these and other elements as we develop our products and technologies, but there are many other factors beyond our control. We may not be able to compete successfully in the future, and increased competition may result in price reductions, reduced profit margins, loss of market share, and an inability to generate cash flows that are sufficient to maintain or expand our development and marketing of new products, which could adversely impact the trading price of the shares of our common stock.

 

17

 

If demand for our STREAMWAY System or molecular diagnostic tests is unexpectedly high or if we experience problems in scaling our operations, there is no assurance that there will not be supply interruptions or delays that could limit the growth of our revenue.

 

We have contracted with a manufacturing company that follows ISO compliance regulations of the FDA and that can manufacture products at high volumes. However, if demand for our product is higher than anticipated, there is no assurance that we or our manufacturing partners will be able to produce the product in sufficiently higher quantity to satisfy demands.

 

Likewise, as demand for our molecular diagnostic tests grow, we will need to continue to scale our testing capacity and processing technology to expand our customer service, billing, and systems processes and to enhance our internal quality assurance program. We will also need additional certified laboratory scientists and other scientific and technical personnel to process higher volumes of our molecular diagnostic tests. We cannot guarantee that increases in scale, related improvements, and quality assurance will be implemented successfully or that appropriate personnel will be available. Failure to implement necessary procedures, transition to new processes, or hire the necessary personnel could result in higher costs of processing tests or an inability to meet demand. There can be no assurance that we will be able to perform our testing on a timely basis at a level consistent with demand, or that our efforts to scale our operations will not negatively affect the quality of test results.

 

If we encounter difficulties in scaling our operations as a result of, among other things, quality control and quality assurance issues and availability of reagents and raw material supplies, we will likely experience reduced sales, increased repair or re-engineering costs, defects, and increased expenses due to switching to alternate suppliers. Any of these results would reduce our revenues and gross margins. Although we attempt to match our capabilities to estimates of marketplace demand, to the extent demand materially varies from our estimates, we may experience constraints in our operations and delivery capacity, which could adversely impact revenue in a given fiscal period. Any supply interruptions or inadequate supply would have a material adverse effect on our results of operations.

 

If we encounter difficulty meeting market demand or quality standards our reputation could be harmed, and our future prospects and business could suffer, causing a material adverse effect on our business, financial condition, and results of operations.

 

We may require additional financing to finance operating expenses and fulfill our business plan. Such financing, if available, will be dilutive.

 

We have not achieved profitability and anticipate that we will continue to incur net losses at least through the remainder of 2022. We may need to raise additional capital to finance operating expenses, invest in our sales organization and new product development, compete in the international marketplace, and develop the strategic assets of our Helomics businesses, especially over the longer term. We would attempt to raise these funds through equity or debt financing that may include public offerings, private placements, alternative offerings, further draws on our equity line with Oasis Capital, LLC, or other means. Such additional financing would be dilutive to existing stockholders, and there is no assurance that such financing would be available upon acceptable terms. If such financing or adequate funds from operations are not available, we would be forced to limit our business activities, which would have a material adverse effect on our results of operations and financial condition. These possibilities, to the extent available, may be on terms that result in significant dilution to our existing shareholders or that result in our existing shareholders losing part or all of their investment.

 

18

 

Our business and operations have been and will likely continue to be materially and adversely affected by the COVID-19 pandemic.

 

The current COVID-19 worldwide pandemic has presented substantial public health challenges. In response to the crisis, emergency measures have been imposed by governments worldwide, including mandatory social distancing and the shutdown of non-essential businesses. These measures have adversely impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets, and our business and operations have been and will likely continue to be materially and adversely affected. For example, our contract manufacturer for the STREAMWAY® System has been forced to change locations, thereby delaying our order fulfillment for parts. We have also reduced on-site staff at several of our facilities, resulting in delayed production, less efficiency, and our sales staff is unable to visit with hospital administrators who are our customers and potential customers. In addition, COVID-19 has impacted the Company’s capital and financial resources, including our overall liquidity position and outlook. For instance, our accounts receivable has slowed while our suppliers continue to ask for pre-delivery deposits. Ultimately, the extent of the impact of the COVID-19 pandemic on our future operational and financial performance will depend on, among other matters, the duration and intensity of the pandemic; the level of success of global vaccination efforts; governmental and private sector responses to the pandemic and the impact of such responses on us; and the impact of the pandemic on our employees, customers, suppliers, operations and sales, all of which are uncertain and cannot be predicted. These factors may remain prevalent for a significant period of time even after the pandemic subsides, including due to a continued or prolonged recession in the U.S. or other major economies. Even in areas where "stay-at-home" restrictions, masking and social distancing measures have been lifted and the number of COVID-19 cases have declined, some jurisdictions may re-impose these measures as and if variant strains emerge or cases rise. The impacts of the COVID-19 pandemic, as with any adverse public health developments, could have a material adverse effect on our business, results of operations, liquidity or financial condition and heighten or exacerbate risks described in this Annual Report on Form 10-K.

 

We are dependent on a few key executive officers for our success. Our inability to retain those officers would impede our business plan and growth strategies, which would have a negative impact on our business and the value of an investment.

 

Our success depends on the skills, experience, and performance of key members of our management team. We heavily depend on our management team: J. Melville Engle, our Chief Executive Officer (“CEO”), and Bob Myers, our Chief Financial Officer (“CFO”). We have entered into employment agreements with the CEO and the CFO and may expand the relatively small number of executives. Were we to lose one or more of these key individuals, we would be forced to expend significant time and money in the pursuit of a replacement, which could result in both a delay in the implementation of our business plan and the diversion of our limited working capital. We can give no assurance that we would be able to find satisfactory replacements for these key individuals at all, or on terms that are not unduly expensive or burdensome to us.

 

If we are required to write down goodwill and other intangible assets, our financial condition and operating results would be negatively affected.

 

When we acquire a business, a substantial portion of the purchase price of the acquisition is allocated to goodwill and other identifiable intangible assets. The amount of the purchase price which is allocated to goodwill and other intangible assets is determined by the excess of the purchase price over the net identifiable assets acquired. For example, when we acquired Helomics, we acquired $3,725,000 in intangible assets and $23,790,290 in goodwill, which represented the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed and represents the future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. We test intangible assets and goodwill for impairment at least annually. During the year ended December 31, 2021, we recorded an impairment of goodwill completing the full impairment of the goodwill acquired at the acquisition of Helomics in 2019. We also recorded a full impairment of the net book value of our intangible assets acquired at the acquisition of Helomics in 2019. On November 24, 2021, we acquired $6,857,790 in goodwill and $3,780,000 of intangible assets as a part of our acquisition of zPREDICTA. Under current accounting standards, if we determine that intangible assets or goodwill are impaired in the future, we will be required to write down these assets. Any write-downs that may be required to be recorded would adversely affect our financial condition and operating results.

 

 

19

 

We may fail to realize the anticipated benefits of the zPREDICTA acquisition.

 

The success of the zPREDICTA acquisition will depend, in part, on our ability to realize the anticipated growth opportunities and synergies from combining our companies, Predictive and zPREDICTA. The integration will be a time consuming and expensive process and may disrupt our operations if it is not completed in a timely and efficient manner. In addition, we may not achieve anticipated synergies or other benefits of the merger. Following the merger, we operate as a combined organization utilizing common information and communication systems, operating procedures, financial controls, and human resources practices. We may encounter the following integration difficulties, resulting in costs and delays:

 

 

failure to successfully manage relationships with customers and other important relationships;

 

failure of customers to continue using our services;

 

difficulties in successfully integrating our management teams and employees;

 

challenges encountered in managing larger operations;

 

losses of key employees;

 

failure to manage our growth and growth strategies;

 

diversion of the attention of management from other ongoing business concerns;

 

incompatibility of technologies and systems;

 

impairment charges incurred to write down the carrying amount of intangible assets generated as a result of the merger; and

 

incompatibility of business cultures.

 

If our operations after the merger do not meet the expectations of our existing or prospective customers, then these customers and prospective customers may cease doing business with us altogether, which would harm our results of operations, financial condition, and business prospects. If the management team is not able to develop strategies and implement a business plan that successfully addresses these difficulties, we may not realize the anticipated benefits of the merger.

 

Risks Related to Our Intellectual Property

 

Our business is dependent upon proprietary intellectual property rights, which if we were unable to protect, could have a material adverse effect on our business. 

 

We rely on a combination of patent, trade secret and other intellectual property rights, contractual restrictions, and other measures to protect our intellectual property. We currently own and may in the future own or license additional patent rights or trade secrets in the U.S., with non-provisional patents elsewhere in the world that cover certain of our products. We rely on patent laws and other intellectual property laws, nondisclosure and other contractual provisions, and technical measures to protect our products and intangible assets.

 

If we fail to protect our intellectual property, third parties may be able to compete more effectively against us and we may incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property. While we apply for patents covering our products and technologies and uses thereof, we may fail to apply for patents on important products and technologies in a timely fashion, or at all, or we may fail to apply for patents in relevant jurisdictions. Others could seek to design around our current or future patented technologies. These intellectual property rights are important to our ongoing operations and no assurance can be given that any measure we implement will be sufficient to protect our intellectual property rights.

 

Further, competitors could willfully infringe upon our intellectual property rights, design around our protected technology, or develop their own competitive technologies that arguably fall outside of our intellectual property rights. Others may independently develop similar or alternative products and technologies or replicate any of our products and technologies. Also, with respect to our trade secrets and proprietary know-how, we cannot be certain that the confidentiality agreements we have entered into with employees will not be breached, or that we will have adequate remedies for any breach. In addition, we may lose the protection afforded by these rights through patent expirations, legal challenges, or governmental action. If our intellectual property does not adequately protect us against competitors’ products and methods, our competitive position could be adversely affected, as could our business and the results of our operations. To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of competition. If our intellectual property does not provide adequate coverage of our competitors’ products, our competitive position could be adversely affected, as could our overall business.

 

20

 

If we become subject to intellectual property actions, it could hinder our ability to deliver our products and services and our business could be negatively impacted.

 

We could be subject to legal or regulatory actions alleging intellectual property infringement or similar claims against us. Companies may apply for or be awarded patents or have other intellectual property rights covering aspects of our technologies or businesses. Litigation may be necessary for us to enforce our patents and proprietary rights or to determine the scope, coverage, and validity of the proprietary rights of others. The outcome of any litigation or other proceeding is inherently uncertain and might not be favorable to us, and we might not be able to obtain licenses to technology that we require on acceptable terms, or at all. Moreover, if it is determined that our products infringe on the intellectual property rights of third parties, we could be prevented from marketing our products. While we are currently not subject to any material intellectual property litigation, any future litigation alleging intellectual property infringement could be costly, particularly in light of our limited resources. Similarly, if we determine that third parties are infringing on our patents or other intellectual property rights, our limited resources may prevent us from litigating or otherwise taking actions to enforce our rights. Any such litigation or inability to enforce our rights could require us to change our business practices, hinder or prevent our ability to deliver our products and services, and result in a negative impact to our business. Expansion of our business via product line enhancements or new product lines to drive increased growth in current or new markets may be inhibited by the intellectual property rights of our competitors and/or suppliers. Our inability to successfully mitigate those factors may significantly reduce our market opportunity and subsequent growth. Any litigation that may be necessary in the future could result in substantial costs and diversion of resources and could have a material adverse effect on our business, financial condition, and operating results.

 

Risk Factors Relating to Regulation

 

Our business is subject to intense governmental regulation and scrutiny, both in the U.S. and abroad.

 

The production, marketing, and R&D of our products is subject to extensive regulation and review by the FDA and other governmental authorities both in the United States and abroad. In addition to testing and approval procedures, extensive regulations also govern marketing, manufacturing, distribution, labeling, and record keeping. If we do not comply with applicable regulatory requirements, violations could result in warning letters, non-approvals, suspensions of regulatory approvals, civil penalties and criminal fines, product seizures and recalls, operating restrictions, injunctions, and criminal prosecution.

 

Periodically, legislative or regulatory proposals are introduced that could alter the review and approval process relating to medical products. It is possible that the FDA will issue additional regulations further restricting the sale of our present or proposed products. Any change in legislation or regulations that governs the review and approval process relating to our current and future products could make it more difficult and costlier to obtain approval for new products, or to produce, market, and distribute existing products.

 

If the FDA begins to enforce regulation of our molecular diagnostic tests, we could incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and costs associated with complying with post-market requirements.

 

Clinical laboratory tests like our molecular diagnostic tests are regulated under CLIA as well as by applicable state laws. Most Laboratory Developed Tests (“LDTs”) are currently not subject to the FDA’s regulation (although reagents, instruments, software, or components provided by third parties and used to perform LDTs may be subject to regulation). In October 2014, the FDA issued two draft guidance documents: “Framework for Regulatory Oversight of Laboratory Developed Tests”, which provides an overview of how the FDA would regulate LDTs through a risk-based approach, and “FDA Notification and Medical Device Reporting for Laboratory Developed Tests”, which provides guidance on how the FDA intends to collect information on existing LDTs, including adverse event reports. On January 13, 2017, the FDA also issued a discussion paper on LDTs. Pursuant to the Framework for Regulatory Oversight draft guidance, LDT manufacturers would be subject to medical device registration, listing, and adverse event reporting requirements. The risk-based classification considers the LDT’s intended use, technological characteristics, and the risk to patients if the LDT were to fail.

 

21

 

Pursuant to the Framework for Regulatory Oversight draft guidance, LDT manufacturers would be required to either submit a pre-market application and receive the FDA’s approval before an LDT may be marketed or submit a pre-market notification in advance of marketing. These requirements would be phased in, starting with higher risk LDTs, following the issuance of the FDA’s final guidance on this topic, which the FDA has identified as a priority. The draft guidance provides that LDTs that are already marketed at the time the final guidance is issued would not be withdrawn from the market during the FDA’s review process.

 

There is no timeframe within which the FDA must issue its final guidance, but issuance of this final guidance has been identified among a list of the FDA’s priorities. As of the date of this filing, the FDA has not issued its final guidance. In August 2020, however, the U.S. Department of Health and Human Services – the parent agency for FDA – announced that the FDA “will not require premarket review of LDTs absent notice-and-comment rulemaking, as opposed to through guidance documents, compliance manuals, website statements, or other informal issuances.” It is unclear at this time whether the Biden Administration will rescind or reverse this policy. It is also unclear at this time when, or if, the FDA will finalize its plans to end enforcement discretion (e.g., via notice and comment rulemaking or otherwise), and even then, the new regulatory requirements are expected to be phased‑in over time. Nevertheless, the FDA may attempt to regulate certain LDTs on a case‑by‑case basis at any time.

 

Legislative proposals addressing the FDA’s oversight of LDTs have been introduced in previous Congresses, and we expect that new legislative proposals will be introduced from time‑to‑time. The likelihood that Congress will pass such legislation and the extent to which such legislation may affect the FDA’s plans to regulate certain LDTs as medical devices is difficult to predict at this time. If the FDA ultimately regulates certain LDTs, whether via final guidance, final regulation, or as instructed by Congress, our molecular diagnostic tests may be subject to certain additional regulatory requirements. The cost of conducting clinical trials and otherwise developing data and information to support pre-market applications may be significant. If we are required to submit applications for our currently marketed tests, we may be required to conduct additional studies, which may be time-consuming and costly and could result in our currently marketed tests being withdrawn from the market. If our tests are allowed to remain on the market, but there is uncertainty in the marketplace about our tests, and if we are required by the FDA to label them investigational, or if labeling claims the FDA allows us to make are limited, orders may decline, and reimbursement may be adversely affected. Continued compliance with the FDA’s regulations would increase the cost of conducting our business, and subject us to heightened regulation by the FDA and penalties for failure to comply with these requirements.

 

In sum, we cannot predict the timing or form of any such guidance or regulation, or the potential effect on our existing molecular diagnostic tests or our tests in development, or the potential impact of such guidance or regulation on our business, financial condition, and results of operations.

 

If we fail to comply with Federal, State, and foreign laboratory licensing requirements, we could lose the ability to perform our tests or experience disruptions to our business.

 

We are subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention, or treatment of disease. CLIA regulations mandate specific standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management, and quality assurance. CLIA certification is also required in order for our business to be eligible to bill Federal and State healthcare programs, as well as many private third-party payors, for our molecular diagnostic tests. To renew these certifications, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our clinical reference laboratories. Pennsylvania laws also require that we maintain a license and establish standards for the day-to-day operation of our clinical reference laboratory in Pittsburgh, Pennsylvania. In addition, our Pittsburgh laboratory is required to be licensed on a test-specific basis by certain other states. If we were unable to obtain or lose our CLIA certificate or State licenses for our laboratories, whether as a result of revocation, suspension, or limitation, we would no longer be able to perform our molecular diagnostic tests, which could have a material adverse effect on our business, financial condition, and results of operations. If we were to lose our licenses issued by the States in which we are required to hold licenses, we would not be able to test specimens from those States. New molecular diagnostic tests we may develop may be subject to new approvals by governmental bodies, and we may not be able to offer our new molecular diagnostic tests to patients in such jurisdictions until such approvals are received.

 

22

 

Complying with numerous statutes and regulations pertaining to our molecular diagnostics business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.

 

We are subject to regulation by both the Federal government and the States in which we conduct our molecular diagnostics business, including:

 

 

The Food, Drug, and Cosmetic Act, as supplemented by various other statutes;

 

The Prescription Drug Marketing Act of 1987, the amendments thereto, and the regulations promulgated thereunder and contained in 21 C.F.R. Parts 203 and 205;

 

CLIA and State licensing requirements;

 

Manufacturing and promotion laws;

 

Medicare and Medicaid billing and payment regulations applicable to clinical laboratories;

 

The Federal Anti-Kickback Statute, which prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual, or the furnishing, arranging for, or recommending of an item or service that is reimbursable, in whole or in part, by a federal healthcare program;

 

The Federal Stark physician self-referral law (and state equivalents), which prohibits a physician from making a referral for certain designated health services covered by the Medicare program, including laboratory and pathology services, if the physician or an immediate family member has a financial relationship with the entity providing the designated health services, unless the financial relationship falls within an applicable exception to the prohibition;

 

The Federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which established comprehensive federal standards with respect to the privacy and security of protected health information and requirements for the use of certain standardized electronic transactions, and amendments made in 2013 to HIPAA under the Health Information Technology for Economic and Clinical Health Act, which strengthen and expand HIPAA privacy and security compliance requirements, increase penalties for violators, extend enforcement authority to state attorneys general, and impose requirements for breach notification;

 

The Federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;

 

The Federal False Claims Act, which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government;

 

Other Federal and State fraud and abuse laws, prohibitions on self-referral, fee-splitting restrictions, prohibitions on the provision of products at no or discounted cost to induce physician or patient adoption, and false claims acts, which may extend to services reimbursable by any third-party payor, including private insurers;

 

The prohibition on reassignment of Medicare claims, which, subject to certain exceptions, precludes the reassignment of Medicare claims to any other party;

 

The rules regarding billing for diagnostic tests reimbursable by the Medicare program, which prohibit a physician or other supplier from marking up the price of the technical component or professional component of a diagnostic test ordered by the physician or other supplier and supervised or performed by a physician who does not “share a practice” with the billing physician or supplier; and

 

State laws that prohibit other specified practices related to billing such as billing physicians for testing that they order, waiving coinsurance, co-payments, deductibles, and other amounts owed by patients, and billing a State Medicaid program at a price that is higher than what is charged to other payors.

 

We have implemented policies and procedures designed to comply with these laws and regulations. We periodically conduct internal reviews of our compliance with these laws. Our compliance is also subject to governmental review. The growth of our business may increase the potential of violating these laws, regulations, or our internal policies and procedures. The risk that we are found in violation of these, or other laws and regulations is further increased by the fact that many have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Violations of Federal or State regulations may incur investigation or enforcement action by the FDA, Department of Justice, State agencies, or other legal authorities, and may result in substantial civil, criminal, or other sanctions. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert managements’ attention from the operation of our business. If our operations are found to be in violation of any of these laws and regulations, we may be subject to civil and criminal penalties, damages, and fines, we could be required to refund payments received by it, we could face possible exclusion from Medicare, Medicaid and other Federal or State healthcare programs, and we could even be required to cease operations. Any of the foregoing consequences could have a material adverse effect on our business, financial condition, and results of operations.

 

23

 

If we use hazardous materials in a manner that causes contamination or injury, we could be liable for resulting damages.

 

We are subject to Federal, State, and local laws, rules and regulations governing the use, discharge, storage, handling, and disposal of biological material, chemicals, and waste. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling, or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, remediation costs, and any related penalties or fines. This liability could exceed our resources or any applicable insurance coverage we may have. The cost of compliance with these laws and regulations may become significant, and our failure to comply may result in substantial fines or other consequences, and either could have a significant impact on our operating results.

 

The healthcare regulatory and political framework is uncertain and evolving.

 

Healthcare laws and regulations are rapidly evolving and may change significantly in the future, which could adversely affect our financial condition and results of operations. For example, in March 2010, the Patient Protection and Affordable Care Act, (“ACA”), was adopted, which is a healthcare reform measure that provided healthcare insurance for approximately 30 million additional Americans. The ACA includes a variety of healthcare reform provisions and requirements that became effective at varying times through 2018 and substantially changed the way healthcare is financed by both governmental and private insurers, which may significantly impact our industry and our business. For instance, the ACA requires “Applicable Manufacturers” to disclose to the Secretary of the Department of Health & Human Services drug sample distributions and certain payments or transfers of value to covered recipients (physicians and teaching hospitals) on an annual basis. “Applicable Manufacturers” and “Applicable Group Purchasing Organizations” must also disclose certain physician ownership or investment interests. The data submitted will ultimately be made available on a public website. Based upon the structure of our relationship with our clients, we may be included in the definition of “Applicable Manufacturer” for purposes of the disclosure requirements or may provide services that include the transfer of drug samples and/or other items of value to covered recipients. As such, we may be required to disclose or provide information that is subject to disclosure. There may be certain risks and penalties associated with the failure to properly make such disclosures, including but not limited to the specific civil liabilities set forth in the ACA, which allows for a maximum civil monetary penalty per “Applicable Manufacturer” of $1,150,000 per year. There may be additional risks and claims made by third parties derived from an improper disclosure that are difficult to ascertain at this time.

 

We cannot predict whether future healthcare initiatives will be implemented at the federal or state level, or how any future legislation or regulation may affect us. The U.S. Supreme Court is currently reviewing the constitutionality of the ACA, although it is unclear when a decision will be made. Further, it is possible that additional governmental action will be taken in response to the COVID-19 pandemic.

 

Risks Related to the Securities Markets and Ownership of Our Common Stock

 

Our certificate of incorporation, as amended, provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the exclusive forum for certain legal actions between us and our stockholders, which could limit our stockholders ability to obtain a judicial forum viewed by the stockholders as more favorable for disputes with us or our directors, officers, or employees.

 

Our certificate of incorporation, as amended, provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (1) any derivative action or proceeding brought on behalf of the corporation, (2) any action asserting a claim of breach of a fiduciary duty owed by any director or officer of the corporation to the corporation or the corporation’s stockholders, (3) any action asserting a claim against the corporation arising pursuant to any provision of the General Corporation Law or the corporation’s Certificate of Incorporation or Bylaws, or (4) any action asserting a claim against the corporation governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, as amended, inasmuch as Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rule and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.

 

24

 

Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees.

 

If a court were to find the choice of forum provision contained in our certificate of incorporation, as amended, to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.

 

Our common stock could be delisted from The NASDAQ Capital Market, which delisting could hinder your ability to obtain accurate quotations on the price of our common stock or dispose of our common stock in the secondary market.

 

On February 17, 2022, we received a letter from the Listing Qualifications Department (the “Staff”) of The NASDAQ Stock Market LLC (“NASDAQ”) informing the Company that because the closing bid price for the Company’s common stock listed on NASDAQ was below $1.00 for 30 consecutive trading days, the Company does not comply with the minimum closing bid price requirement for continued listing on The NASDAQ Capital Market under NASDAQ Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no immediate effect on the listing of the Company’s common stock.

 

In accordance with NASDAQ’s Marketplace Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until August 16, 2022, to regain compliance with the Minimum Bid Price Requirement. If at any time before August 16, 2022 the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, NASDAQ will provide written notification that the Company has achieved compliance with the Minimum Bid Price Requirement.

 

The letter also disclosed that in the event the Company does not regain compliance with the Minimum Bid Price Requirement by August 16, 2022, the Company may be eligible for additional time. To qualify for additional time, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The NASDAQ Capital Market, with the exception of the bid price requirement, and would need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Staff would notify the Company that its securities would be subject to delisting. In the event of such notification, the Company may appeal the Staff’s determination to delist its securities, but there can be no assurance the Staff would grant the Company’s request for continued listing.

 

25

 

The Company intends to continue actively monitoring the bid price for its common stock between now and August 16, 2022 and will consider available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.

 

In the event our common stock is delisted from The NASDAQ Capital Market and we are also unable to maintain listing on another alternate exchange, trading in our common stock could thereafter be conducted in FINRA’s OTC Bulletin Board or in the over-the-counter markets in the so-called pink sheets. In such event, the liquidity of our common stock would likely be impaired, not only in the number of shares which could be bought and sold, but also through delays in the timing of the transactions, and there would likely be a reduction in our coverage by security analysts and the news media, thereby resulting in lower prices for our common stock than might otherwise prevail.

 

Limitations on director and officer liability and indemnification of our officers and directors by us may discourage stockholders from bringing a suit against a director.

 

Our Certificate of Incorporation and Bylaws provide, with certain exceptions as permitted by governing state law, that a director or officer shall not be personally liable to us or our stockholders for breach of fiduciary duty as a Director, except for acts or omissions which involve intentional misconduct, fraud, knowing violation of law, or unlawful payments of dividends. These provisions may discourage stockholders from bringing a suit against a director for breach of fiduciary duty and may reduce the likelihood of derivative litigation brought by stockholders on our behalf against a director. In addition, our certificate of incorporation and bylaws may provide for mandatory indemnification of directors and officers to the fullest extent permitted by governing state law.

 

We do not expect to pay dividends for the foreseeable future, and we may never pay dividends; investors must rely on stock appreciation, if any, for any return on investment in our common stock.

 

We currently intend to retain any future earnings to support the development and expansion of our business and do not anticipate paying cash dividends in the foreseeable future. Our payment of any future dividends will be at the discretion of our Board of Directors after taking into account various factors, including but not limited to, our financial condition, operating results, cash needs, growth plans, and the terms of any credit agreements that we may be a party to at the time. In addition, our ability to pay dividends on our common stock may be limited by state law. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize certain returns on their investment. As a result, investors must rely on stock appreciation and a liquid trading market for any return on investment in our common stock.

 

Our Board of Directors ability to issue undesignated preferred stock and the existence of anti-takeover provisions may depress the value of our common stock.

 

Our authorized capital includes 20 million shares of preferred stock. Of this amount and 79,246 shares have been designated as series B convertible preferred stock and the remaining authorized shares are undesignated preferred stock. Our Board of Directors has the power to issue any or all of the shares of undesignated preferred stock, including the authority to establish one or more series and to fix the powers, preferences, rights, and limitations of such class or series, without seeking stockholder approval. Further, as a Delaware corporation, we are subject to provisions of the Delaware General Corporation Law regarding business combinations. We may, in the future, consider adopting additional anti-takeover measures. The authority of our Board of Directors to issue undesignated stock and the anti-takeover provisions of Delaware law, as well as any future anti-takeover measures adopted by us, may, in certain circumstances, delay, deter, or prevent takeover attempts and other changes in control not approved by our Board of Directors. As a result, our stockholders may lose opportunities to dispose of their shares at favorable prices generally available in takeover attempts or that may be available under a merger proposal and the market price, voting, and other rights of the holders of common stock may also be affected.

 

26

 

General Risk Factors

 

Our success is dependent on our ability to attract and retain technical personnel, sales and marketing personnel, and other skilled management.

 

Our success depends to a significant degree on our ability to attract, retain, and motivate highly skilled and qualified personnel. Failure to attract and retain necessary technical, sales and marketing personnel, and skilled management could adversely affect our business. If we fail to attract, train, and retain sufficient numbers of these highly qualified people, our business, financial condition, and results of operations could be materially and adversely affected.

 

Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments is limited by provisions of the Internal Revenue Code and may be subject to further limitation because of prior or future offerings of our stock or other transactions.

 

Sections 382 and 383 of the United States Internal Revenue Code of 1986, as amended (the “Code”) contain rules that limit the ability of a company that undergoes an ownership change, which is generally an increase in the ownership percentage of certain stockholders in the stock of a company by more than 50% over a three-year period, to utilize its net operating loss and tax credit carryforwards and certain built-in losses recognized in years after the ownership change. These rules generally operate by focusing on ownership changes involving stockholders owning directly or indirectly 5% or more of the stock of a company and any change in ownership arising from a new issuance of stock by that company. Generally, if an ownership change, as defined by Section 382 of the Code, occurs, the yearly taxable income limitation on the use of net operating loss and tax credit carryforwards and certain built-in losses is equal to the product of the applicable long-term tax-exempt rate and the value of stock immediately before the ownership change. We have not assessed the potential impact of Sections 382 and 383.

 

Costs incurred because we are a public company may affect our profitability.

 

As a public company, we incur significant legal, accounting, and other expenses and are subject to the SEC’s rules and regulations relating to public disclosure that generally involve a substantial expenditure of financial resources.  In addition, the Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the SEC, require changes in corporate governance practices of public companies. Full compliance with such rules and regulations requires significant legal and financial compliance costs and makes some activities more time-consuming and costlier, which may negatively impact our financial results. To the extent our earnings suffer as a result of the financial impact of our SEC reporting or compliance costs, our ability to develop an active trading market for our securities could be harmed.

 

Shares eligible for future sale may adversely affect the market.

 

From time to time, certain stockholders may be eligible to sell some or all of their shares of common stock pursuant to Rule 144, promulgated under the Securities Act subject to certain limitations. In general, pursuant to Rule 144 as in effect as of the date of this filing, a stockholder (or stockholders whose shares are aggregated) who has satisfied the applicable holding period and is not deemed to have been one of our affiliates at the time of sale, or at any time during the three months preceding a sale, may sell their shares of common stock. Any substantial sale, or cumulative sales, of our common stock pursuant to Rule 144 or pursuant to any resale prospectus may have a material adverse effect on the market price of our securities.

 

We expect volatility in the price of our common stock, which may subject us to securities litigation.

 

The market for our common stock may be characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will be more volatile than a seasoned issuer for the indefinite future. In the past, plaintiffs have often initiated securities class action litigation against companies following periods of volatility in the market price of their securities. We may in the future be the target of similar litigation. Securities litigation could result in substantial costs and liabilities and could divert management’s attention and resources.

 

Acquisitions involve risks that could result in adverse changes to operating results, cash flows, and liquidity.

 

We may desire to make strategic acquisitions in the future. However, we may not be able to identify suitable acquisition opportunities, or we may be unable to obtain the consent of our stockholders and therefore, may not be able to complete such acquisitions. We may pay for acquisitions with our common stock or with convertible securities, which may dilute shareholders’ investment in our common stock, or we may decide to pursue acquisitions that our investors may not agree with. In connection with potential acquisitions, we may agree to substantial earn-out arrangements. To the extent we defer the payment of the purchase price for any acquisition through a cash earn-out arrangement, cash flows will be reduced in subsequent periods.

 

27

 

In addition, acquisitions, including our recent acquisition of zPREDICTA, Inc. may expose us to operational challenges and risks, including:

 

the ability to profitably manage acquired businesses or successfully integrate the operations of acquired businesses, as well as the acquired business’s financial reporting and accounting control systems into our existing platforms;

​increased indebtedness and contingent purchase price obligations associated with an acquisition;

​the ability to fund cash flow shortages that may occur if anticipated revenue is not realized or is delayed, whether by general economic or market conditions, or unforeseen internal difficulties;

​the availability of funding sufficient to meet increased capital needs;

​diversion of management’s time and attention from existing operations; and

​the ability to retain or hire qualified personnel required for expanded operations.

 

Completing acquisitions may require significant management time and financial resources because we may need to assimilate widely dispersed operations with different corporate cultures. In addition, acquired companies may have liabilities that we failed to or were unable to discover in the course of performing due diligence investigations. We cannot assure the shareholders’ that the indemnification granted by sellers of acquired companies will be sufficient in amount, scope, or duration to fully offset the possible liabilities associated with businesses or properties we assume upon consummation of an acquisition. We may learn additional information about our acquired businesses that could have a material adverse effect on us, such as unknown or contingent liabilities and liabilities related to compliance with applicable laws. Any such liabilities, individually or in the aggregate, could have a material adverse effect on our business. Failure to successfully manage the operational challenges and risks associated with, or resulting from, acquisitions could adversely affect our results of operations, cash flows, and liquidity. Borrowings or issuances of convertible securities associated with these acquisitions may also result in higher levels of indebtedness, which could adversely impact our ability to service our debt within the scheduled repayment terms.

 

Security breaches, loss of data and other disruptions to our business or the business of our third-party service providers could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and reputation.

 

Our business requires that we collect and store sensitive data, including protected health and credit card information and proprietary business and financial information. We face a number of risks relative to the protection of, and the service providers’ protection of, this critical information, including loss of access, inappropriate disclosure, and inappropriate access, as well as risks associated with our ability to identify and audit such events. The secure processing, storage, maintenance, and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or otherwise breached due to employee error, malfeasance, or other activities. While we have not experienced any such attack or breach, if such event would occur and cause interruptions in our operations, our networks could be compromised and the information we store on those networks could be accessed by unauthorized parties, publicly disclosed, lost, or stolen. Unauthorized access, loss, or dissemination could disrupt our operations, including collecting, processing, and preparing company financial information, managing the administrative aspects of our business, and damaging our reputation, any of which could adversely affect our business. In addition, the interpretation and application of consumer, health-related, and data protection laws in the United States are often uncertain, contradictory, and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. Complying with these various laws could cause us to incur substantial costs or require us to change our business practices, systems, and compliance procedures in a manner adverse to our business. Additionally, in connection with the ongoing COVID-19 pandemic, many of our employees have the ability to work remotely, which may increase the risk of security breaches, loss of data, and other disruptions as a consequence of more employees accessing sensitive and critical information from remote locations.

 

28

 

If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures in connection with security incidents, we may suffer loss of reputation, financial loss, and civil or criminal fines or other penalties. In addition, these breaches and other forms of inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above.

 

If our information technology and communications systems fail or we experience a significant interruption in our operation, our reputation, business, and results of operations could be materially and adversely affected.

 

The efficient operation of our business is dependent on information technology and communications systems. The failure of these systems to operate as anticipated could disrupt our business and result in decreased revenue and increased overhead costs. In addition, we do not have complete redundancy for all of our systems and our disaster recovery planning cannot account for all eventualities. Our information technology and communications systems, including the information technology systems and services that are maintained by third-party vendors, are vulnerable to damage or interruption from natural disasters, fire, terrorist attacks, malicious attacks by computer viruses or hackers, and power loss or failure of computer systems, Internet, telecommunications or data networks. If these systems or services become unavailable or suffer a security breach, we may expend significant resources to address these problems, and our reputation, business, and results of operations could be materially and adversely affected.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS.

 

Not applicable.

 

ITEM 2. PROPERTIES.

 

Our corporate offices are located in Eagan, Minnesota. We lease 5,773 square feet at this location, of which 2,945 square feet is used for office space and 2,828 is used for manufacturing. The lease as amended has a one-year term that ended January 31, 2022, and as of December 10, 2021 has a second amended six-month term until July 31, 2022. Management and the landlord have orally agreed to further extensions as needed.

 

The offices of our Helomics subsidiary are located in Pittsburgh, Pennsylvania. We lease 17,417 square feet at this location, of which approximately 1,000 square feet are used for office space and 16,417 square feet is used for laboratory operations. The lease, as amended, has a two-year term ending February 28, 2023.

 

zPREDICTA’s offices are located in San Jose, California. We lease approximately 1,236 square feet at this location. The lease is month-to-month tenancy.

 

Soluble Biotech’s offices are located in Birmingham, Alabama. We lease approximately 5,274 square feet at this location. The lease is effective through August 25, 2025.

 

TumorGenesis’s offices are located in Salem, Massachusetts. We lease approximately 1,450 square feet at this location. The lease is effective through May 31, 2023.

 

We expect that the current space will be adequate for our current office and laboratory needs.

 

ITEM 3. LEGAL PROCEEDINGS.

 

Not applicable.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

29

 

PART II

 

ITEM 5. MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

 

Market Information

 

Effective June 13, 2019, our common stock was listed on the NASDAQ Capital Market under the symbol “POAI”. Prior to this, effective February 2, 2018, our common stock was listed on the NASDAQ Capital Market under the symbol “AIPT”. Prior to February 2, 2018, our common stock was listed on The NASDAQ Capital Market under the symbol “SKLN”.

 

Holders

 

As of March [22], 2022, there were approximately [157] stockholders of record of our common stock.

 

Dividend Policy

 

We follow a policy of retaining earnings, if any, to finance the expansion of our business. We have not paid, and do not expect to declare or pay, cash dividends on common stock in the foreseeable future.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

The information required by Item 5 is incorporated herein by reference to Item 12 below.

 

Recent Sales of Unregistered Securities

 

Information regarding sales of unregistered securities during the periods covered hereby has been included in previous reports on Form 8-K or 10-Q. For additional information on such sales, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources – Financing Transactions.”

 

ITEM 6. SELECTED FINANCIAL DATA.

 

Not Required.

 

ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Information Regarding Forward-Looking Statements

 

This Annual Report on Form 10-K contains “forward-looking statements” that indicate certain risks and uncertainties, many of which are beyond our control. Actual results could differ materially and adversely from those anticipated in such forward-looking statements as a result of certain factors, including those set forth below and elsewhere in this report. Important factors that may cause actual results to differ from projections include:

 

 

We may not be able to continue operating without additional financing;

 

Current negative operating cash flows;

 

Our capital needs to accomplish our goals, including any further financing, which may be highly dilutive and may include onerous terms;

 

Risks related to recent and future acquisitions, including the possibility of impairment of goodwill and risks related to the benefits and costs of acquisition;

 

Risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns;

 

Risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property;

 

30

 

 

The impact of competition;

 

Acquisition and maintenance of any necessary regulatory clearances applicable to applications of our technology;

 

Risk we may not be able to attract or retain qualified senior management personnel, including sales and marketing personnel;

 

Risk that we never become profitable if our products and services are not accepted by potential customers;

 

Possible impact of government regulation and scrutiny;

 

Unexpected costs and operating deficits, and lower than expected sales and revenues, if any;

 

Adverse results of any legal proceedings;

 

The volatility of our operating results and financial condition,

 

Management of growth; and

 

Risk that our business and operations will continue to be materially and adversely affected by the COVID-19 pandemic, which has impacted on a significant supplier; has resulted in delayed production and less efficiency; and has impacted on our sales efforts, accounts receivable, and terms demanded by suppliers; and may impact financing transactions; and

 

Other specific risks that may be alluded to in this report.

 

All statements, other than statements of historical facts, included in this report regarding our growth strategy, future operations, financial position, estimated revenue or losses, projected costs, prospects and plans, and objectives of management are forward-looking statements. When used in this report, the words “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “plan,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements speak only as of the date of this report. We do not undertake any obligation to update any forward-looking statements or other information contained herein. Potential investors should not place undue reliance on these forward-looking statements. Although we believe that our plans, intentions, and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure potential investors that these plans, intentions or expectations will be achieved. We disclose important factors that could cause actual results to differ materially from expectations in the “Risk Factors” section and elsewhere in this report. These cautionary statements qualify all forward-looking statements attributable to us or persons acting on our behalf.

 

Information regarding market and industry statistics contained in this report is included based on information available to us that we believe is accurate. It is generally based on academic and other publications that are not produced for purposes of securities offerings or economic analysis. We have not reviewed or included data from all sources, and we cannot assure potential investors of the accuracy or completeness of the data included in this report. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue, and market acceptance of products and services. We have no obligation to update forward-looking information to reflect actual results or changes in assumptions or other factors that could affect those statements.

 

Overview

 

We operate in four primary business areas: first, the application of artificial intelligence (“AI”) in our precision medicine business, to provide AI-driven predictive models of tumor drug response to improve clinical outcomes for patients and to assist pharmaceutical, diagnostic, and biotech industries in the development of new personalized drugs and diagnostics; second, creation of tumor-specific 3D cell culture models driving accurate prediction of clinical outcomes; third, contract services and research focused on solubility improvements, stability studies, and protein production and; fourth, production of the United States Food and Drug Administration (“FDA”)-cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products

 

We have four reportable segments: Helomics®, zPREDICTA®, SolubleTM and Skyline®. The Helomics segment includes clinical testing and contract research services that include the application of AI. Our zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. Our Soluble segment provides services using a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. Our Skyline segment consists of the STREAMWAY System product sales, and our TumorGenesis subsidiary is included within corporate. Going forward, we have determined that we will focus our resources on the Helomics and zPREDICTA segments and our primary mission statements to accelerate patient-centric drug discovery to improve patient outcomes in cancer treatment, harnessing the power of AI, and to develop tumor-specific 3D cell culture models that provide accurate 3D reconstruction of human tissues representing each cancer disease state.

 

31

 

Capital Requirements

 

Since inception, we have been unprofitable. We incurred net losses of $19,657,174 and $25,884,397 for the years ended December 31, 2021, and December 31, 2020, respectively. As of December 31, 2021, and December 31, 2020, we had an accumulated deficit of $128,040,282 and $108,383,108, respectively.

 

We have never generated sufficient revenues to fund our capital requirements. Since 2017, we have diversified our business by investing in ventures, including making significant loans and investments in early-stage companies. These activities led to the acquisition of Helomics in April 2019, the purchase of the assets of two businesses in 2020 and the acquisition of zPREDICTA in November 2021, each of which have accelerated our capital needs. We have funded our operations through a variety of debt and equity instruments. See “Liquidity and Capital Resources – Liquidity and Plan of Financing” and “Liquidity and Capital Resources – Financing Transactions” below.

 

Our future cash requirements and the adequacy of available funds depend on our ability to generate revenues from our Helomics and zPREDICTA segments; our ability to continue to sell our Skyline Medical products and to reach profitability in the Skyline Medical business, our ability to generate revenue from our Soluble reportable segment and the availability of future financing to fulfill our business plans. See “Liquidity and Capital Resources – Liquidity and Plan of Financing” below.

 

Our limited history of operations, especially in our precision medicine business, and our change in the emphasis of our business, starting in 2017, makes prediction of future operating results difficult. We believe that period-to-period comparisons of our operating results should not be relied on as predictive of our future results.

 

Results of Operations

 

Comparison of Year Ended December 31, 2021 with Year Ended December 31, 2020

 

   

2021

   

2020

   

Difference

 

Revenue

  $ 1,420,680     $ 1,252,272     $ 168,408  

Cost of goods sold

    487,024       447,192       (39,832 )

General and administrative expense

    10,932,125       10,351,973       (580,152 )

Operations expense

    2,698,565       2,351,709       (346,856 )

Sales and marketing expense

    774,530       584,937       (189,593 )

 

Revenue. We recorded revenue of $1,420,680 in 2021, compared to $1,252,272 in 2020. Our Skyline division was responsible for the majority of the revenue, with Soluble generating $233,293 and $2,870 and Helomics generating $13,367 and $64,188 in revenue in the years ended December 31, 2021 and 2020, respectively. We sold 15 STREAMWAY System units in 2021 and 25 STREAMWAY System units in 2020.

 

Cost of sales. Cost of sales was $487,024 and $447,192 in 2021 and 2020, respectively. The increase in cost of sales is primarily due to increased cost of disposables and costs associated with our repair and maintenance contracts The gross profit margin was 66% in 2021 compared to 64% in 2020. Our margins increased in 2021 due to higher margins associated with our Soluble operating segment and from our Skyline Medical operating segment disposable product margins.

 

32

 

General and Administrative expense. General and administrative (“G&A”) expense primarily consists of management salaries, professional fees, consulting fees, travel expense, administrative fees and general office expenses.

 

G&A expense increased by $580,152 to $10,932,125 in 2021 from $10,351,973 in 2020. The increase was primarily due to increases in staff related expenses including additional headcount, as well as certain one-time expenses related to severance incurred as part of the departure of our former CEO. Additional increases included higher costs for consulting expenses and fees to our Board of Directors. Also, increased depreciation was driven by newly added assets supporting our Helomics division. These increases were offset by lower share-based compensation and lower costs for investor relations.

 

Operations expense. Operations expense in our current stage primarily consists of expenses related to product development, prototyping and testing including staff related expenses for individuals performing this work.

 

Operations expense increased by $346,856 to $2,698,565 in 2021 compared to $2,351,709 in 2020. The increase in operations expense in 2021 was primarily due to higher payroll costs and higher costs associated with cloud computing, offset by decreased costs associated with consulting.

 

Sales and marketing expense. Sales and marketing expense consists of expenses required to sell products through independent reps, attendance at trade shows, product literature and other sales and marketing activities.

 

Sales and marketing expenses increased by $189,593 to $774,530 in 2021 compared to $584,937 in 2020. The increase in 2021 was due to increased expenses in web development, public relations, and market research.

 

Loss on goodwill impairment. We incurred a loss on impairment of goodwill of $2,813,792 and $12,876,498 during 2021 and 2020, respectively, all relating to the goodwill acquired in the Helomics acquisition in 2019. Our goodwill, for our Helomics operating segment, following the impairment was $0 and $2,813,792 at December 31, 2021 and December 31, 2020, respectively. The cumulative losses on goodwill are $23,790,290 as of December 31, 2021. See Note 10 to our audited consolidated financial statements included in this annual report.

 

Loss on intangible asset impairment. We incurred a loss on impairment of intangibles of $2,893,548 during the year ended December 31, 2021. The impairment recorded relates to the intangible assets of our Helomics operating segment and none of the Company’s other operating segments. The value of the intangible assets of the Helomics operating segment following the impairment was $0 at December 31, 2021. See Note 10 to our audited consolidated financial statements included in this annual report.

 

Loss on impairment of acquired software. We incurred a loss on impairment on acquired software of $1,249,727 during the year ended December 31, 2021. The impairment recorded relates to the acquired software asset of our Helomics operating segment and none of the Company’s other operating segments. The value of the acquired software asset of the Helomics operating segment following the impairment was $0 at December 31, 2021. Please see Note 10 to our audited consolidated financial statements included in this annual report for further information.

 

Other income. We earned other income of $184,528 in 2021 compared to $843,440 in 2020. Other income included interest income and gains on settlement of outstanding payables during 2021. Other income was comprised of gain on the forgiveness of the Paycheck Protection Program loan of $541,867 and gains on settlement of outstanding payables during 2020.

 

Other expense. We incurred other expenses of $239,631 in 2021 compared to $2,427,026 in 2020. Other expenses consisted primarily of interest expense, payment penalties and amortization of original issue discounts.

 

Gain on derivative instruments. We incurred a gain of $164,902 in 2021 compared to a gain of $1,765,907 in 2020, primarily related to the changes in fair market value on derivatives.

 

Gain on notes receivable associated with asset purchase. We recorded a gain of $1,290,000 in 2020 related to the gain on notes receivable in connection with our acquisition of certain assets in 2020.

 

33

 

Income Taxes. We recognized $661,658 income tax benefit in our consolidated statement of net loss in the year ended December 31, 2021 related to the release of the valuation allowance following the zPREDICTA acquisition and zero related to our U.S. operating losses, as all tax benefits are fully reserved.

 

Liquidity and Capital Resources

 

Cash Flows

 

Net cash used in operating activities was $12,208,929 in 2021, compared with net cash used of $12,257,732 in 2020. Cash used in operating activities increased in 2021 primarily due to operating losses as well as outflows related to payments on accounts payables and payments for accrued expenses, inventories and prepaid expenses.

 

Cash flows used in investing activities were $10,607,536 in 2021, and $167,456 in 2020. Cash flows used in investing activities in 2021 were primarily related to the acquisition of our zPREDICTA subsidiary in the amount of $9,590,214 and $910,429 of cash outflows related to purchases of fixed assets. Cash flows used in investing activities in 2020 were primarily for purchases of fixed assets, offset by disposals of fixed assets.

 

Net cash provided by financing activities was $50,340,748 in 2021 compared to net cash provided of $12,952,689 in 2020. Cash flows provided by financing activities in 2021 were primarily due from proceeds from the issuance of common stock and warrants of $50,523,527 in several equity offerings and proceeds from the exercise of warrants into common stock of $4,513,871, offset by repayment of debt and payment penalties of $5,236,214.

 

Liquidity and Plan of Financing

 

Since our inception, we have incurred significant losses, and our accumulated deficit was $128,040,282 as of December 31, 2021. We have committed significant capital and management resources to develop our CRO business and other new business areas and intend to continue to devote significant resources to the Helomics and zPREDICTA business and other new business in this market. Our business will need to generate significantly more revenue to sufficiently fund our operations without external financing. Our operations from inception have been funded with private placements of convertible debt securities and equity securities, public offerings, and loan agreements. We have not achieved profitability and anticipate that we will continue to incur net losses at least through the remainder of 2022. We had revenues of $1,420,680 and $1,252,272 in 2021 and 2020, respectively, but we had negative operating cash flows of $12,208,929 and $12,257,732 in 2021 and 2020, respectively. Our cash balance was $28,202,615 as of December 31, 2021, and our accounts payable and accrued expenses were an aggregate $2,284,415. See “Financing Transactions” below.

 

We believe that our existing capital resources will be sufficient to support our operating plan for the next twelve months and beyond. However, we may also seek to raise additional capital to support our growth through additional debt, equity or other alternatives or a combination thereof. We would raise such capital through equity or debt financing to fund our capital and equipment investments and our operations.

 

Financing Transactions

 

We have funded our operations through a combination of debt and equity instruments including an early bank loan (since repaid), and a variety of debt and equity offerings. Since late 2018, these financing transactions have consisted of (1) secured convertible notes to private investors starting in late 2018, the remaining amount of which was repaid on March 1, 2021; (2) a series of loans from Dr. Carl Schwartz, our former CEO, starting in late 2018, which were exchanged for common stock in 2020; and (3) a number of public offerings, registered direct offerings and private placements, including an equity line arrangement (offerings), since 2019.

 

34

 

2021 Offerings

 

In January and February 2021, the Company completed a series of five offerings, all of which were priced at-the-market under applicable NASDAQ rules. The first four offerings were registered direct offerings of common stock under its shelf registration statement, and in each such case, in a concurrent private placement, the Company also issued such investors one warrant to purchase common stock for each two shares purchased in the transaction. Following those four offerings, the Company completed a private placement of common stock, with each investor receiving one warrant to purchase common stock for each two shares purchased in the transaction. In June 2021, the Company completed a registered direct offering of common stock and warrants. The warrants became exercisable on the effective date of an increase in the number of shares of the Company’s authorized common stock, which occurred on August 17, 2021, and expire three years after the initial exercise date. In each case, each such investor warrant is exercisable immediately upon issuance and will expire five and one-half years from the issue date. In each case, the Company paid to the placement agent an aggregate fee equal to 7.5% of the aggregate gross proceeds received by the Company in the offering and a management fee equal to 1% of the aggregate gross proceeds received by the Company in the offering and reimbursed the placement agent for certain non-accountable and out-of-pocket expenses. In addition, the Company granted to the placement agent, or its assigns warrants to purchase 7.5% of the shares sold to investors in the offering at an exercise price equal to 125% of the price of the shares in the transaction, with a term of five years for the registered direct offerings (three years for the June 2021 offering) or five and one-half years for the private placement.

 

These 2021 offerings were as follows:

 

Offering Closing Date

Shares

Sale Price per Share*

Investor Warrants

Exercise Price per Share investor Warrants

Placement Agent Warrants

Exercise Price per Share Placement Agent Warrants

Gross Proceeds of Offering

Net Proceeds of Offering

January 12, 2021

(registered direct)

3,650,840

$0.842

1,825,420

$0.80

273,813

$1.0525

$3,074,007

$2,731,767

January 21, 2021

(registered direct)

2,200,000

$1.00

1,100,000

$1.00

165,000

$1.25

$2,200,000

$1,932,050

January 26, 2021

(registered direct)

3,414,970

$1.20

1,707,485

$1.20

256,123

$1.50

$4,097,964

$3,668,687

February 16, 2021

(registered direct)

4,222,288

$1.75

2,111,144

$2.00

316,672

$2.1875

$7,389,004

$6,679,989

February 23, 2021

(private placement)

9,043,766

$1.95

4,521,883

$2.00

678,282

$2.4375

$17,635,344

$16,064,739

June 16, 2021

(registered direct)

15,520,911

$1.375

15,520,911

$1.25

1,164,068

$1.71875

$21,341,252

$19,446,296

Total

38,057,775

 

26,786,843

 

2,853,958

 

$55,737,571

$50,523,528

* Sale price includes one share and a warrant to purchase one-half share (or one whole share in the case of the June 16, 2021 offering).

 

35

 

Secured Notes and Repayment in Full

 

On March 1, 2021, the Company used $5,906,802 of the proceeds of the private placement on February 23, 2021, described above under “2021 Offerings”, to repay in full the outstanding principal and interest and applicable premium amounts under the convertible secured promissory notes to two private investors in the original principal amount of an aggregate $2,297,727 issued in September 2018, the secured promissory note with a principal amount of $847,500 issued during September 2019 and the secured promissory note with a principal amount of $1,450,000 issued on February 5, 2020.

 

2021 Warrant Exercises

 

During the year ended December 31, 2021, the holders of outstanding investor warrants have exercised such warrants for the total purchase of 5,269,059 shares at a weighted average exercise price of $0.86 per share, for total proceeds of $4,513,871.

 

Equity Line

 

On October 24, 2019, the Company entered into an equity purchase agreement with an investor, providing for an equity financing facility. Upon the terms and subject to the conditions in the purchase agreement, the investor is committed to purchase shares having an aggregate value of up to $15,000,000 of the Company’s common stock for a period of up to three years. The Company issued to the investor 104,651 commitment shares at a fair market value of $450,000 for entering into the agreement. From time to time during the three-year commitment period, provided that the closing conditions are satisfied, the Company may provide the investor with put notices to purchase a specified number of shares subject to certain limitations and conditions and at specified prices, which generally represent discounts to the market price of the common stock. As of December 31, 2021, there was $9,113,829 of remaining available balance under the equity line, subject to shareholder approval required for additional purchases, as well as requirements for market conditions including trading volume and stock price, and subject to other limitations. During the year ended December 31, 2021, the Company issued 647,504, shares of its common stock valued at $675,590 pursuant to the equity line.

 

Dr. Schwartz Notes

 

In November 2018, Dr. Schwartz made a loan to the Company with a principal balance of $370,000. As of December 31, 2018, one promissory note was held with a principal balance of $370,000 and an unamortized discount of $63,028. From November 30, 2018 through July 15, 2019, Dr. Schwartz made numerous loans to the Company in the total amount of $1,920,000 under two promissory notes. As consideration for these amounts, Dr. Schwartz received promissory notes and warrants to purchase 22,129 shares of the Company’s common stock at $8.36 per share. Further, beginning on February 1, 2019 and the first day of each calendar month thereafter while the note remained outstanding, a number of additional warrants were issued. Beginning in October 2019, the Company and Dr Schwartz began to renegotiate the note. Due to the negotiations, the Company did not issue any additional warrants because they would be cancelled under the new deal.

 

During January 2020, the Company entered into an exchange agreement with Dr. Schwartz. Under the exchange agreement, the two outstanding notes were cancelled and in exchange a new combined promissory note in the amount of $2,115,000 (the “2020 Schwartz Note”) bearing 12% interest per annum and maturing on September 30, 2020 was issued. In addition to the 2020 Schwartz Note, Dr. Schwartz received 50,000 shares of the Company’s common stock. All warrants issued under the prior promissory notes were cancelled under the exchange agreement; no rights and obligations remain under the cancelled notes. The Company determined that the exchange agreement had, in substance, occurred at December 31, 2019.

 

Effective as of April 21, 2020, the Company and Dr. Schwartz, entered into an exchange agreement relating to the 2020 Schwartz Note. The 2020 Schwartz Note bore twelve percent (12%) interest per annum and had a maturity date of September 30, 2020. The accrued interest on the note through April 21, 2020 was $77,878, resulting in a total balance of $2,192,878 in principal and accrued interest on the 2020 Schwartz Note as of such date. Dr. Schwartz and the Company agreed to exchange the 2020 Schwartz Note for newly issued shares of common stock of the Company at market value. Pursuant to the exchange agreement, Dr. Schwartz was issued 1,533,481 shares of newly issued common stock at an exchange rate of $1.43 per share, equal to the closing price of the common stock on April 21, 2020. In 2021, the Company determined that due to a calculation error, the balance of the 2020 Schwartz Note should have been higher by $143,573 at the time of the exchange agreement, and on February 24, 2021, the Company issued an additional 100,401 shares to Dr. Schwartz.

 

36

 

2020 Offerings

 

On March 19, 2020, in a private placement we sold and issued (1) 260,000 shares of common stock, at a sale price of $2.121 per share; (2) prefunded warrants to acquire 1,390,166 shares of common stock, sold at $2.12 per share and exercisable at an exercise price of $0.001 per share; (3) warrants to acquire 1,650,166 shares of common stock at $1.88 per share, exercisable immediately and terminating five and one-half years after the date of issuance; and (4) warrants to acquire 1,650,166 shares of common stock at $1.88 per share, exercisable immediately and terminating two years after the date of issuance. The sale resulted in gross proceeds of $3,498,612 and net proceeds of $3,127,112. The Company paid the Placement Agent an aggregate fee equal to 7.5% of the aggregate gross proceeds received by the Company in the offering. The Company also paid the Placement Agent a management fee equal to 1% of the aggregate gross aggregate gross proceeds received by the Company in the offering and reimbursed the Placement Agent for $25,000 in non-accountable expenses and up to $40,000 in legal and other out-of-pocket expenses. In addition, the Company granted to the Placement Agent, or its assigns warrants to purchase up to an aggregate of 123,762 shares of its common stock (which represents 7.5% of the Shares sold to investors in the private placement) at an exercise price equal to 125% of the price of the Shares in the private placement, or $2.65125. These placement agent warrants will expire on March 18, 2025.

 

During May 2020, the Company sold 1,396,826 shares of common stock in a registered direct offering under its shelf registration statement. In a concurrent private placement, the Company also issued such investors warrants to purchase up to an aggregate of 1,396,826 shares of our common stock. The Shares and the Warrants were sold at a combined offering price of $1.575 per Share and associated Warrant. Each Warrant is exercisable immediately upon issuance at an exercise price of $1.45 per share and will expire five and one-half years from the issue date. The sale of the offering shares and associated warrants resulted in gross proceeds of $2,200,001 and net proceeds of $1,930,100 after deducting the placement agent fees and estimated offering expenses payable by the Company. The Company granted to the placement agent, or its assigns warrants to purchase up to an aggregate of 104,762 shares of its common stock at an exercise price of $1.9688.

 

On June 25, 2020, the Company entered into agreements with the holders of an aggregate of 1,396,826 of the warrants issued in connection with the May 2020 registered direct offering, under which the investors exercised the warrants and received the same number new warrants. The investors paid an exercise price of $1.45 per share plus an additional $0.125 for each new warrant. The Company issued 1,396,826 shares and issued new warrants which are exercisable immediately and have a term of five and one-half years and an exercise price per share equal to $1.80. The Company received $2,130,701 in gross proceeds and net proceeds of $1,865,800 after deducting the placement agent fees and estimated offering expenses payable by the Company. Before deducting placement agent fees and expenses, the Company received approximately $2,200,000 from the transactions.  Pursuant to an engagement letter, the Company agreed to pay the Placement Agent a cash fee equal to 7.5% of the gross proceeds received from the exercise and the sale of the New Warrants. The Company also paid the Placement Agent a management fee equal to 1% of the aggregate gross aggregate gross proceeds received by the Company in the offering and reimbursed the Placement Agent for $25,000 in non-accountable expenses and up to $40,000 in legal and other out-of-pocket expenses. In addition, the Company granted to the Placement Agent, or its assigns warrants to purchase up to an aggregate of 104,763 shares of its common stock (which represents 7.5% of the shares sold to investors in the exercise transaction) at an exercise price equal to 125% of the exercise price of the New Warrants, or $2.25.

 

In connection with the equity line arrangement entered into with Oasis Capital, LLC (“Oasis”) in October 2019, during the year ended December 31, 2020, we issued an aggregate 4,231,073 shares of common stock to Oasis for net proceeds of $4,891,348.

 

2020 Conversions

 

In June through September 2019, the Company entered into a private placement securities purchase agreement with investors for shares of Series E convertible preferred stock. The Company issued 258 preferred shares. In May 2020, we notified the holders of our Series E Convertible Preferred Stock of our election to convert the outstanding shares of Series E Stock into common stock effective on June 13, 2020 pursuant to the terms of the Series E Stock. Prior to the conversion, there were 207.7 shares of Series E Stock outstanding. Each share of Series E Stock converted into 0.056857% of the issued and outstanding shares of common stock immediately prior to conversion; therefore, the 207.7 outstanding shares of Series E Stock on June 13, 2020 converted into 1,257,416 shares of common stock equal to 11.8% of the outstanding shares of common stock as of June 12, 2020.

 

37

 

2020 Paycheck Protection Program Loan and Forgiveness

 

On April 20, 2020, the Company entered into a promissory note with Park State Bank, which provides for an unsecured loan of $541,867 pursuant to the Paycheck Protection Program (the “PPP”) under the Coronavirus Aid, Relief, and Economic Security Act and applicable regulations (the “CARES Act”). The promissory note has a term of 2 years with a 1% per annum interest rate. Payments are deferred for 6 months from the date of the promissory note and the Company can apply for forgiveness of all or a portion of the promissory note after 60 days for covered use of funds.

 

Pursuant to the terms of the PPP, the promissory note, or a portion thereof, may be forgiven if proceeds are used for qualifying expenses as described in the CARES Act, such as payroll costs, costs used to continue group health care benefits, mortgage interest payments, rent and utilities. The Company has used all proceeds for qualifying expenses. The Company received forgiveness for the loan under the Paycheck Protection Program and recognized a gain in other income for the full amount of the loan during the fourth quarter of 2020.

 

Issuances of Securities in Acquisitions

 

On April 4, 2019, the Company completed a forward triangular merger with Helomics Acquisition Inc., a wholly-owned subsidiary of the Company and Helomics, acquiring the remaining 75% of the capital stock of Helomics not already held by the Company. Upon the acquisition, all outstanding shares of Helomics stock not already held by the Company were converted into the right to receive a proportionate share of 400,000 shares of common stock and 3,500,000 shares of Series D convertible preferred stock of the Company. On April 4, 2020, the 3,500,000 shares of Series D convertible preferred stock were converted into 350,004 shares of common stock. Also, on April 4, 2019, the Company completed an exchange offer with the holders of certain notes and warrants of Helomics, in which the Company issued 863,732 shares of common stock to the noteholders in exchange for their notes and issued warrants to purchase up to 1,425,506 shares of common stock of the Company at an exercise price of $10.00 per share in exchange for the Helomics warrants held by the noteholders. An additional 59,700 Company warrants at an exercise price of $0.10 per share were exchanged for Helomics warrants held by other parties. On September 14, 2020, the Company agreed to amend the 1,425,506 Company warrants that were originally exercisable at $10.00 per share to allow the holders to exercise the warrants at an exercise price of $0.845 per share, equal to the then-current market value of the common stock.

 

On May 27, 2020, the Company entered into an Asset Purchase Agreement with InventaBioTech, Inc. (“InventaBioTech”) and two of its subsidiaries, Soluble Therapeutics, Inc. (“Soluble”), and BioDtech, Inc. (“BioDtech”), and simultaneously completed the acquisition of substantially all of Soluble’s and BioDtech’s assets. In exchange, the Company issued 125,000 shares of common stock and waived all existing claims that the Company has or may have against InventaBioTech (f/k/a CytoBioscience, Inc.), including the nonpayment of $1,290,000 owed by InventaBioTech to the Company. See Note 5 to the Consolidated Financial Statements.

 

On July 1, 2020, the Company entered into an Asset Purchase Agreement with Quantitative Medicine LLC (“Seller”), a Delaware limited liability company and its owners and simultaneously completed the acquisition of substantially all of the assets owned by Seller. Quantitative Medicine is a biomedical analytics and computational biology company that developed a novel, computational drug discovery platform called CoRE. CoRE is designed to dramatically reduce the time, cost, and financial risk of discovering new therapeutic drugs by predicting the main effects of drugs on target molecules that mediate disease. In exchange for Seller’s assets, including CoRE, the Company provided consideration in the form of 954,719 shares of common stock, which, when issued, had a fair value of $1,470,267. One half of the shares issued, or 477,359 shares were deposited and held in escrow upon issuance, while 207,144 of the remaining shares were issued to Carnegie Mellon University (“CMU”) in satisfaction of all pre-closing amounts owed to CMU under a technology licensing agreement that was assumed by the Company on the closing date. Half of the shares held in escrow will be released on the six-month anniversary of the closing date, and the other half will be released on the one-year anniversary of the closing date; provided, however, that all or some of the escrow shares may be released and returned to the Company for reimbursement in the event that the Company suffers a loss against which the Selling Parties have indemnified the Company pursuant to the Agreement. See Note 5 to the Consolidated Financial Statements.

 

38

 

Critical Accounting Policies and Estimates

 

The discussion and analysis of our financial condition and results of operations are based upon our audited consolidated Financial Statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of our financial statements, the reported amounts of revenues and expenses during the reporting periods presented, as well as our disclosures of contingent assets and liabilities. On an on-going basis, we evaluate our estimates and assumptions, including, but not limited to, fair value of stock-based compensation, fair value of acquired intangible assets and goodwill, useful lives of intangible assets and fixed assets and income taxes.

 

We base our estimates and assumptions on our historical experience and on various other information available to us at the time that these estimates and assumptions are made. We believe that these estimates and assumptions are reasonable under the circumstances and form the basis for our making judgments about the carrying values of our assets and liabilities that are not readily apparent from other sources.  Actual results and outcomes could differ from our estimates primarily due to incorrect sales forecasting. We utilize a pipeline generated by our sales team and speak directly with all departments regarding estimates and assumptions. If, for any reason, those estimates, and assumptions vary substantially it would also impact our cost of goods and associated operating expenses. The other volatile area for estimates and assumptions is determining financing needs. Depending on how we choose to fund will affect numerous expense categories so the potential for underestimating those expenses is a viable concern.

 

Our significant accounting policies are described in “Note 1 – Summary of Significant Accounting Policies,” in Notes to audited consolidated Financial Statements of this Annual Report on Form 10-K. We believe that the following discussion addresses our critical accounting policies and reflects those areas that require more significant judgments and use of estimates and assumptions in the preparation of our audited consolidated Financial Statements.

 

Revenue Recognition.  We recognize revenue in accordance with ASC 606, Revenue Recognition.

 

Effective January 1, 2018, we adopted Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606), which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard’s core principle is that an entity will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

 

Revenue from Product Sales. We have medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within both the domestic and international revenue segments. We sell our medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. Our sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. We consider the combination of a purchase order and acceptance of our Terms and Conditions to be a customer’s contract in all cases.

 

Product sales for medical devices consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (1) we have transferred physical possession of the products, (2) we have a present right to payment, (3) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from our facilities (“FOB origin,” which is our standard shipping terms). As a result, we determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. We may, at our discretion, negotiate different shipping terms with customers which may affect the timing of revenue recognition. Our standard payment terms for customers are generally 30 to 60 days after we transfer control of the product to the customer. We allow returns of defective disposable merchandise if the customer requests a return merchandise authorization from us.

 

39

 

Customers may also purchase a maintenance plan for the medical devices from us, which requires us to service the STREAMWAY System for a period of one year subsequent to the one-year anniversary date of the original STREAMWAY System invoice. The maintenance plan is considered a separate performance obligation from the product sale, is charged separately from the product sale, and is recognized over time (ratably over the one-year period) as maintenance services are earned and provided. A time-elapsed output method is used to measure progress because we transfer control evenly by providing a stand-ready service. We have determined that this method provides a faithful depiction of the transfer of services to our customers.

 

All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold.

 

Revenue from Clinical Testing. Clinic diagnostic testing is comprised of our Tumor Drug Response Testing (ChemoFx) and Genomic Profiling (BioSpeciFx) tests. The Tumor Drug Response Testing test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the Genomic Profiling test evaluates the expression and/or status of a particular gene related to a patient’s tumor specimen. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Payments terms vary for contracts and services sold by our Helomics subsidiary. Our performance obligations are satisfied at one point in time when test reports are delivered, and studies are completed.

 

For service revenues, we estimate the transaction price which is the amount of consideration we expect to be entitled to receive in exchange for providing services based on our historical collection experience using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. We monitor our estimates of transaction price to depict conditions that exist at each reporting date. If we subsequently determine that we will collect more consideration than we originally estimated for a contract with a patient, we will account for the change as an increase to the estimate of the transaction price, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized.

 

We recognize revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers are established at the amount of consideration to which we expect to be entitled or when we receive substantially all of the consideration subsequent to the performance obligations being satisfied.

 

CRO Revenue. Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. We typically use an input method that recognizes revenue based on our efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, we allocate the contract’s transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 from the invoice date, which is sent to the customer as we satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation.

 

Variable Consideration. We record revenue from distributors and direct end customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. Our current contracts do not contain any features that create variability in the amount or timing of revenue to be earned.

 

Warranty. We generally provide one-year warranties against defects in materials and workmanship on product sales and will either repair the products or provide replacements at no charge to customers. As they are considered assurance-type warranties, we do not account for them as separate performance obligations. Warranty reserve requirements are based on a specific assessment of the products sold with warranties where a customer asserts a claim for warranty or a product defect. 

 

40

 

Contract Balances. We record a receivable when we have an unconditional right to receive consideration after the performance obligations are satisfied. Our deferred revenues relate primarily to maintenance plans and CRO revenue.

 

Practical Expedients. We have elected the practical expedient not to determine whether contracts with customers contain significant financing components as well as the practical expedient to recognize shipping and handling costs at point of sale.

 

Stock-Based Compensation.  We account for share-based compensation expense in accordance with ASC 718, CompensationStock Compensation, which requires us to measure and recognize compensation expense in our financial statements based on the fair value at the date of grant for our share-based awards. We recognize compensation expense for these equity-classified awards over their requisite service period and adjust for forfeitures as they occur.

 

ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. We use the Black-Scholes option-pricing model which requires the input of significant assumptions including an estimate of the average period of time employees and directors will retain vested stock options before exercising them, the estimated volatility of our common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements and the risk-free interest rate.

 

When an option or warrant is granted in place of cash compensation for services, we deem the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason we also use the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period that investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of our common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognizes that. We have been on the NASDAQ Capital Market since 2015 and have had a volatile stock including reverse stock splits. The assumptions we use in calculating the fair value of stock-based payment awards represent our best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and we use different assumptions, our equity-based consulting and interest expense could be materially different in the future.

 

In the case of standard options to employees we determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, we estimated the life to be the legal term unless there was a compelling reason to make it shorter.

 

Business Combination. We accounted for the zPREDICTA merger as a business combination, using the acquisition method of accounting. This method requires, among other things, that assets acquired, and liabilities assumed be recognized at fair value as of the acquisition date. The fair value for the assets acquired and the liabilities assumed are based on information knowable and determined by management as of the acquisition date. We allocate the purchase price to tangible and intangible assets acquired and liabilities assumed, based on their estimated fair values. The excess of the purchase price, if any, over the aggregate fair value of assets acquired and liabilities assumed is allocated to goodwill. 

 

Fixed Assets. We account for assets acquired at fair value as of the acquisition date. The fair value for assets acquired are based on their estimated fair values. Fixed assets are stated at cost less accumulated depreciation. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets.

 

41

 

Goodwill and Other Intangible Impairment. In accordance with ASC 350, Intangibles Goodwill and Other, goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of net assets acquired. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination. Goodwill is an indefinite-lived intangible asset and is not amortized. 

 

Goodwill is not amortized but is tested on an annual basis for impairment at the reporting unit level as of December 31, or whenever events or changes in circumstances indicate that the carrying amount may not be fully recoverable.

 

To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first has the option to assess qualitative factors to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using discounted cash flows. To determine fair values, the Company is required to make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations including the rate of future revenue growth, capital requirements, and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. These assumptions require significant judgement. Pursuant to ASU 2017-04, Simplifying the Test for Goodwill Impairment, the single step is to determine the estimated fair value of the reporting unit and compare it to the carrying value of the reporting unit, including goodwill. To the extent the carrying amount of goodwill exceeds the implied goodwill, the difference is the amount of the goodwill impairment. The Company also completes a reconciliation between the implied equity valuation prepared and the Company’s market capitalization. The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 inputs. The inputs for the market capitalization calculation are considered Level 1 inputs. See Note 10 – Intangible Assets and Goodwill.

 

In the Helomics acquisition, the Company recorded goodwill of $23,790,290. The goodwill was recorded to the Helomics segment which represents a single reporting unit. The cumulative losses on goodwill are $23,790,290 as of December 31, 2021. See Note 10 to our audited consolidated financial statements included in this annual report.

 

On November 24, 2021, the Company acquired goodwill of $6,857,790 in connection with the acquisition of zPREDICTA. The Company determined the value of the goodwill associated with the zPREDICTA reporting unit was fully recoverable at December 31, 2021.

 

Long-lived Assets

 

The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which the Company operates.

 

The Company prepared an undiscounted cash flow as of December 31, 2021 to evaluate long-lived assets based on a triggering event per ASC 360. The Company concluded that the undiscounted cash flows did not support the carrying values of its the long-lived assets within the Helomics asset group at December 31, 2021. The Company determined the value of the intangibles and the software license acquired were fully impaired as of December 31, 2021 and recognized an impairment loss on its long-lived intangible assets of $2,893,548 and $1,249,727 impairment loss related to the acquired software. See Note 10 – Intangible Assets and Goodwill.

 

Based on a triggering event as of December 31, 2020, the Company prepared an undiscounted cash flows per ASC 360 to evaluate its other long-lived assets. The Company concluded that the undiscounted cash flows of the long-lived assets exceeded the carrying values. The Company concluded there was no impairment of its finite lived assets as of December 31, 2020.

 

42

 

Income Taxes. Deferred income taxes are provided on a liability method, whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards. Deferred tax liabilities are recognized for taxable temporary differences, which are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

 

Recent Accounting Developments

 

See “Note 1 - Summary of Significant Accounting Policies - Recently Adopted Accounting Standards” in Notes to Consolidated Financial Statements of this Annual Report on Form 10-K.

 

Off-Balance Sheet Transactions

 

We have no off-balance sheet transactions.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not required.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

 

Our financial statements and supplementary data are included beginning on pages F-1 of this report.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES.

 

Disclosure Controls and Procedures

 

Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), defines the term “disclosure controls and procedures” as those controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as of December 31, 2021. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective as of December 31, 2021.

 

43

 

Managements Report on Internal Control Over Financial Reporting

 

We are responsible for establishing and maintaining adequate internal control over financial reporting. As defined in the securities laws, internal control over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officer and effected by our Board of Directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the acquisitions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

 

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we carried out an evaluation of the effectiveness of our internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) as of December 31, 2021 based on the criteria in “Internal Control - Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in 2013. Based upon this evaluation, we concluded that our internal control over financial reporting were effective as of December 31, 2021.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) during the three months ended December 31, 2021 that has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B. OTHER INFORMATION.

 

None.

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

The Board may be increased or decreased from time to time by resolution of the stockholders or the Board. Our Board presently consists of seven directors. Directors are elected at each annual meeting, and each director shall serve until his or her term expires, his or her earlier death, or a successor is elected and qualified or until the director resigns or is removed. Directors are elected by the highest number of votes cast at a meeting at which a quorum is present. Any vacancies may be filled by the vote of a majority of the Board of Directors, although less than a quorum, and any such person elected to fill a vacancy shall serve as a director until the next annual meeting of stockholders.

 

The Board does not intend to alter the manner in which it evaluates candidates for the Board based on whether or not the candidate was recommended by a stockholder. To submit a candidate for consideration for nomination, stockholders must submit such nomination in writing to our Secretary at 2915 Commers Drive, Suite 900, Eagan, MN 55121.

 

Executive Officers and Directors of the Registrant

 

The following table identifies our executive officers and directors for the year ended December 31, 2021:

 

Name

 

Age

Position Held

       

J. Melville Engle

 

71

Chief Executive Officer and Chairman of the Board of Directors

       

 

44

 

Bob Myers

 

67

Chief Financial Officer

       

Chuck Nuzum

(1) (2) (3) (5)

73

Director

       

Daniel E. Handley, Ph.D.

(3)

62

Director

       

Gregory S. St. Clair

(1)

56

Director

       

Nancy Chung-Welch, Ph.D.

(1) (2) (4) (5)

61

Director

       

Christina Jenkins, M.D.

 (4)

50

Director

       

Raymond F. Vennare

(3)

69

Director

       

 

 

(1)

Member of the Audit Committee

 

(2)

Member of the Compensation Committee

 

(3)

Member of the Nominating and Governance Committee

 

(4)

Member of the Merger & Acquisition Committee

 

(5)

Member of the Finance Committee

 

J. Melville Engle was appointed Chief Executive Officer on March 19, 2021. Mr. Engle resigned from the Compensation and Governance Committees concurrently with his appointment as CEO.

 

Each director will serve until their successors are elected and have duly qualified.

 

There are no family relationships among our directors and executive officers. Our executive officers are appointed by our Board of Directors and serve at the Board’s discretion.

 

Classified Board of Directors

 

On March 22, 2019, our stockholders approved amendments to the Certificate of Incorporation and Bylaws to establish a classified Board of Directors, and we filed the Amended and Restated Certificate of Incorporation. The amendments to our Certificate of Incorporation and Bylaws provide for the division of the members of our shareholders into three classes, with the term of each class expiring in different years. As a result of this stockholder approval, three classes of directors were created: Class I continuing for a term expiring in 2022, Class II for a term expiring in 2023, and Class III for a term, expiring in 2024. Beginning with the 2019 annual meeting of stockholders, the class of directors up for election or reelection will be elected to three-year terms. The current directors are divided into classes as follows:

 

CLASS I

(term expiring in 2022)

CLASS II

(term expiring in 2023)

CLASS III

(term expiring in 2024)

Chuck Nuzum

Daniel E. Handley

J. Melville Engle

Nancy Chung-Welch

Gregory S. St. Clair

Christina Jenkins

Raymond Vennare

 

Business Experience

 

J. Melville Engle, Chief Executive Officer, and Chairman of the Board of Directors. Effective March 19, 2021, J. Melville Engle was appointed our Chief Executive Officer. Mr. Engle had served as a director since 2016. He became the Chairman of the Board in January 2020. Mr. Engle has worked in the healthcare industry for the past three decades. Since 2012, he had served as President and Chief Executive Officer of Engle Strategic Solutions, a consulting company focused on CEO development and coaching, senior management consulting, corporate problem solving and strategic and operational planning. He was a director of Windgap Medical, Inc., and has held executive positions at prominent companies including Chairman and Chief Executive Officer at ThermoGenesis Corp., Regional Head/Director, North America at Merck Generics, President and Chief Executive Officer of Dey, L.P. and CFO, at Allergan, Inc. In addition to ThermoGenesis, he has served on the Board of Directors of several public companies, including Oxygen Biotherapeutics and Anika Therapeutics. Mr. Engle holds a BS in Accounting from the University of Colorado and an MBA in Finance from the University of Southern California. He has served as a Trustee of the Queen of the Valley Medical Center Foundation, was a Board Member of the Napa Valley Community Foundation, and at the Napa College Foundation. He was also Vice Chair of the Thunderbird Global Council at the Thunderbird School of Global Management in Glendale, Arizona.

 

45

 

Bob Myers, Chief Financial Officer. Effective July 1, 2012, Mr. Myers was appointed as our Chief Financial Officer. Mr. Myers was our Acting Chief Financial Officer and Corporate Secretary since December 2011. He has over 40 years’ experience in multiple industries focusing on medical device, service and manufacturing and prior to joining the Company was a financial contractor represented by various contracting firms in the Minneapolis area. He has spent much of his career as a Chief Financial Officer and/or Controller. Mr. Myers was a contract CFO at Disetronic Medical, contract Corporate Controller for Diametric Medical Devices and contract CFO for Cannon Equipment. Previously he held executive positions with American Express, Capitol Distributors, and International Creative Management and was a public accountant with the international firm of Laventhol & Horwath. Mr. Myers has an MBA in Finance from Adelphi University and a BBA in Public Accounting from Hofstra University.

 

Daniel E. Handley M.S., Ph.D., Director. Dr. Handley was appointed to the Board on February 19, 2020. He serves as a Professor and the Director of the Clinical and Translational Genome Research Institute of Southern California University of Health Sciences. Previously, he was the Chief Scientific Officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)3 non-profit corporation. During that time, he also held a courtesy faculty appointment in the Department of Biological Sciences at Florida Gulf Coast University. He previously served as the Chief Scientific Officer for Advanced Healthcare Technology Solutions, Inc., Life-Seq, LLC, as a senior researcher at the Procter & Gamble Co., a senior administrator, researcher, and laboratory manager at the David Geffen UCLA School of Medicine, and as a founding biotechnology inventor for the National Genetics Institute. He holds a B.A. in Biophysics from Johns Hopkins University, an M.S. in Logic and Computation from Carnegie Mellon University, a Ph.D. in Human Genetics from the University of Pittsburgh. He completed his post-doctoral training at Magee-Women’s Research Institute researching advanced genomic technologies applied to fetal and maternal health. He is a veteran of the U.S. Navy, having served as a nuclear propulsion instructor and a submarine nuclear reactor operator.

 

Chuck Nuzum. Mr. Nuzum was appointed to the Board on July 9, 2020. Mr. Nuzum has extensive experience as a CFO that ranges from private start-ups to large publicly-traded companies. Mr. Nuzum presently provides financial consulting services on a project basis to companies such as McKesson, BioMarin, AutoDesk and Squire Patton Boggs, mentors start-up companies and serves on the Board of Directors of several companies. Previously he was co-founder and CFO of the Tyburn Group, a financial services company that creates and delivers prepaid payroll and general purpose card programs for customers. For the four years prior, Mr. Nuzum served as the Controller of Dey, L.P., a large pharmaceutical manufacturing subsidiary of Merck KGaA. Prior to that he was co-founder, Executive Vice President and CFO of SVC Financials Services, one of the first companies in the field to integrate a mobile money solution for global distribution, Vice President of Finance and Administration at Tiburon, Inc., a leader in public safety and justice information systems, and CFO of Winebid.com the world’s leading e-commerce wine auction company. For more than two decades, Mr. Nuzum was CFO of Loomis Fargo & Co., the well-known international provider of ATM systems, armored cars and other security services. Mr. Nuzum, a Certified Public Accountant, earned his BA at the University of Washington at Seattle.

 

Gregory S. St. Clair. Mr. St. Clair was appointed to the Board on July 9, 2020. Mr. St. Clair is the Founder and Managing Member of SunStone Consulting, LLC, a healthcare consulting firm that serves healthcare providers throughout the United States since 2002. As frequently sought experts on issues related to compliance, reimbursement and revenue integrity, Mr. St. Clair and his team are constantly on-call to assist clients as they address financial challenges through creative solutions to the nation’s health systems. Previously, Mr. St. Clair worked as a national vice president for CGI, ImrGlobal, and Orion Consulting and as national director for Coopers & Lybrand. He holds a B.S. in both Accounting and Finance from Juniata College in Huntington, Pennsylvania.

 

46

 

Nancy Chung-Welch, Ph.D. Dr. Chung-Welch was appointed to the Board on July 9, 2020. Dr. Chung-Welch is currently an independent consultant advising life science companies and their institutional investors on life science companies, technologies and industries with an emphasis on the research product/tools market. Previously she was a Director, Business Development at Cell Signaling Technology and was Director, Business Development at Thermo Fisher Scientific and Technical Marketing Manager for Fisher Scientific. She has over 25 years of marketing and business development experience in the life sciences market. Dr. Chung-Welch has a balanced blend of business and technical/analytical strengths to provide sound foundation for technology/IP assessments and external partnerships. She has a strong record of domestic and international experience in business and customer needs analysis, technology assessment, licensing, distribution deals, partnerships, strategic alliances, strategic customer relationships, mergers/acquisitions. She previously served as Instructor in Surgery and Assistant in Physiology at Harvard Medical School and the Massachusetts General Hospital with expertise in basic science research, including cell biology, tissue culture, vascular physiology, genomics, proteomics, and lab automation applications. She is also a hands-on marketing executive and has conceptualized, launched, and managed products and services in the laboratory, medical, biotech/pharma, academic and government markets. She received her Ph.D. in Vascular Physiology and Cell Biology from Boston University.

 

Christina Jenkins, M.D. was appointed to the Board on April 21, 2021. Dr. Jenkins is a strategic advisor and venture investor whose expertise spans clinical medicine, venture capital, health systems and health plans. She applies her unique perspective of providers, payers and consumers to help leaders optimize growth and health outcomes. Currently, Dr. Jenkins is a Venture Partner at Phoenix Venture Partners (PVP), where she co-leads the firm’s seed-stage investment strategy in the healthcare/life sciences vertical. She is focused on hardware-enabled platform companies that are transforming the way we diagnose, monitor and treat health conditions. Dr. Jenkins also leads investments for Portfolia, Inc.’s FemTech and Active Aging and Longevity funds, focusing on evidence-backed digital health and device companies targeting the health of women. She also is a director of Independence Health Group (the parent company of Independence Blue Cross and AmeriHealth Caritas), a board of directors observer at Madorra Inc., and an advisory board member of multiple value-generating healthcare companies. Dr. Jenkins is also a member of the Kauffman Fellows, a global leadership program in venture capital, completing her fellowship at New Enterprise Associates. Previously, she was the founding CEO of OneCity Health Services, a subsidiary of NYC Health + Hospitals, building a team from two to 130 and leading a successful $1.2 billion effort to design and implement technology-enabled care models and accelerate value-based payment (financial risk) readiness for one million lives. She was also a Clinical Instructor in Internal Medicine at Mount Sinai Medical Center in New York City, and began her career as a financial analyst (FMP) with GE Healthcare. She earned her M.D. from Northwestern University Medical School, where she was Class President, and her B.S. in Industrial Management at Purdue University.

 

Raymond F. Vennare was appointed to the Board on September 13, 2021. Mr. Vennare brings more than thirty years of experience to his work as an accomplished senior executive, board director and biotechnology entrepreneur. As a professional who has built and managed companies on behalf of institutional investors, private foundations and research institutions, he is recognized as an expert in the practice of company creation, technology commercialization, business development and corporate governance. Mr. Vennare is currently (and has been since 2015), Chairman of the Board and CEO of Cvergenx, Inc., a genomic informatics company developing decision-support tools for radiation oncology, and since 2019 has been on the Board of Directors of Cvergenx Technologies India Private, Ltd. He also serves as a trusted and confidential advisor to clients as diverse as nationally ranked universities and philanthropic foundations to multi-national publicly traded companies and early-stage start-ups. Previously Mr. Vennare was Co-founder, President and CEO of ThermalTherapeutic Systems, Inc. (Medical Device); President and Chief Executive Officer of ImmunoSite, Inc. (Diagnostics); Senior Vice President and Chief Information Officer, TissueInformatics, Inc. (Bioinformatics); Founder, President and Partner in VSInteractive (Information Technology) and, Founder and President of the Fine Art Inventory Network (On-line Commerce). From June 2018 to December 2020, he was Vice Chairman of Guangzhou INDA Biotechnology Company, Ltd. Mr. Vennare has a Master’s Degree in Business and Ethics from Duquesne University, a Master’s Degree in Art History and Museum Studies from Case Western Reserve University and a Bachelor’s Degree from the University of Pittsburgh.

 

Richard L. Gabriel resigned as a member of the Board of Directors effective May 1, 2021. Mr. Gabriel’s resignation is in connection with his assuming a management position with the Company.

 

47

 

Board Committee Structures

 

The Board of Directors has determined that each current member of the Audit Committee, the Compensation Committee and the Nominating and Governance Committee meets the applicable SEC and NASDAQ rules and regulations regarding “independence” and that each member is free of any relationship that would impair their individual exercise of independent judgment with regard to us.

 

Below is a description of each committee of the Board of Directors as such committees are presently constituted.

 

Audit Committee

 

The Audit Committee was established by the Board in accordance with Section 3(a)(58)(A) of the Exchange Act to oversee our corporate accounting and financial reporting processes and audits of our financial statements.

 

All members of the Audit Committee are independent directors. Pursuant to its charter and the authority delegated to it by the Board of Directors, the Audit Committee has sole authority for oversight of our independent registered public accounting firm. In addition, the Audit Committee reviews the results and scope of the audit and other services provided by our independent registered public accounting firm, and also reviews our accounting and control procedures and policies. The Audit Committee meets as often as it determines necessary but not less frequently than once every fiscal quarter.

 

Our Audit Committee currently consists of Mr. Nuzum, as the chairperson, Mr. St. Clair and Dr. Chung-Welch. During 2020, the Audit Committee chairperson was Ms. Prior, who was replaced on the committee and as chairperson by Mr. Nuzum in July 2020. Each Audit Committee member is a non-employee director of the Board. The Board of Directors has determined that all current members of our Audit Committee are independent. The Audit Committee met eight times in fiscal 2021.

 

Audit Committee Financial Expert

 

The Board has determined that Mr. Nuzum meets the criteria as an “audit committee financial expert,” as defined in Item 407(d)(5)(ii) of Regulation S-K under the Securities Act of 1933, as amended. As noted above, Mr. Nuzum, Mr. St. Clair, and Dr. Chung-Welch are independent within the meaning of NASDAQ’s listing standards.

 

Compensation Committee

 

The Compensation Committee of the Board of Directors currently consists of three directors, Mr. Nuzum, as the chairperson, Dr. Chung-Welch and Mr. St. Clair. The members of the Compensation Committee were appointed by the Board of Directors and consist entirely of directors who are “outside directors” for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended, “non-employee directors” for purposes of Rule 16b-3 under the Exchange Act and “independent” as independence is currently defined in Rule 4200(a) (15) of the NASDAQ listing standards. In fiscal 2021, the Compensation Committee met eight times. The functions of the Compensation Committee include, among other things:

 

 

approving the annual compensation packages, including base salaries, incentive compensation, deferred compensation and stock-based compensation, for our executive officers;

     
 

administering our stock incentive plans, and subject to Board approval in the case of executive officers, approving grants of stock, stock options and other equity awards under such plans;

     
 

approving the terms of employment agreements for our executive officers;

     
 

developing, recommending, reviewing and administering compensation plans for members of the Board of Directors;

     
 

reviewing and discussing the compensation discussion and analysis with management; and

     
 

preparing any compensation committee report required to be included in the annual proxy statement.

 

48

 

All Compensation Committee approvals regarding compensation to be paid or awarded to our executive officers are rendered with the full power of the Board, though not necessarily reviewed by the full Board.

 

Our Chief Executive Officer may not be present during any Board or Compensation Committee voting or deliberations with respect to his compensation. Our Chief Executive Officer may, however, be present during any other voting or deliberations regarding compensation of our other executive officers but may not vote on such items of business.

 

Compensation Committee Interlocks and Insider Participation

 

As indicated above, the Compensation Committee consists of Mr. Nuzum, Dr. Chung-Welch and Mr. St. Clair. No member of the Compensation Committee has ever been an executive officer or employee of ours. None of our officers currently serves, or has served during the last completed year, on the compensation committee or the Board of Directors of any other entity that has one or more officers serving as a member of the Board of Directors or the Compensation Committee.

 

Nominating and Governance Committee

 

The Nominating and Governance Committee of the Board of Directors currently consists of Dr. Handley, as the chairperson Mr. Nuzum and Mr. Vennare. All members of the Nominating and Governance Committee are “independent directors,” as such term is defined by The NASDAQ Market Listing Rule 5605(a)(2), and free from any relationship that, in the opinion of the Board, would interfere with the exercise of his or her independent judgment as a member of the Committee.

 

The members of the Committee shall be elected annually by the Board. Committee members may be removed for any reason or no reason at the discretion of the Board, and the Board may fill any Committee vacancy that is created by such removal or otherwise. The Committee’s chairperson shall be designated by the full Board or, if it does not do so, the Committee members shall elect a chairperson upon the affirmative vote of a majority of the directors serving on the Committee. In fiscal 2021, the Nominating and Governance Committee met four times

 

The Committee may form and delegate authority to subcommittees as it may deem appropriate in its sole discretion.

 

In furtherance of its purposes, the Committee:

 

 

Evaluates the composition, organization and governance of the Board, determines future requirements and make recommendations to the Board for approval;

     
 

Determines desired Board and committee skills and attributes and criteria for selecting new directors;

     
 

Reviews candidates for Board membership consistent with the Committee’s criteria for selecting new directors or as recommended by our stockholders. Annually, the Committee recommends a slate of nominees to the Board for consideration at our annual stockholders’ meeting;

     
 

Develops a plan for, and consults with the Board regarding, management succession; and

     
 

Advises the Board generally on corporate governance matters.

 

In addition, the Committee, if and when deemed appropriate by the Board or the Committee, develops and recommends to the Board a set of corporate governance principles applicable to the Company, and reviews and reassesses the adequacy of such guidelines annually and recommends to the Board any changes deemed appropriate. The Committee also advises the Board on (1) committee member qualifications, (2) appointments, removals and rotation of committee members, (3) committee structure and operations (including authority to delegate to subcommittees), and (4) committee reporting to the Board. Finally, the Committee performs any other activities consistent with its charter, our Certification of Incorporation, Bylaws and governing law as the Committee or the Board deems appropriate.

 

49

 

The Committee has the authority to obtain advice and seek assistance from internal or external legal, accounting or other advisors. The Committee has the sole authority to retain and terminate any search firm to be used to identify director candidates, including sole authority to approve such search firm’s fees and other retention terms.

 

Merger & Acquisition Committee

 

The Merger & Acquisition Committee of the Board of Directors currently consists of, Dr. Jenkins, as the chairperson, and Dr. Chung-Welch and Mr. Engle. The Merger & Acquisition Committee advises the Company with respect to any considered mergers, acquisitions, joint ventures and/or consolidations of any type.

 

Diversity

 

The Board of Directors currently has no formal policy regarding attaining diversity on the Board.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our officers and directors, and persons who own more than ten percent of a registered class of our equity securities, to file reports of ownership and changes in ownership of such securities with the Securities and Exchange Commission. Officers, directors and greater than ten percent stockholders are required by Securities and Exchange Commission regulations to furnish us with copies of all Section 16(a) forms they file. Based solely on review of the copies of Forms 3 and 4 and amendments thereto furnished to us during the fiscal year ended December 31, 2021 and Forms 5 and amendments thereto furnished to us with respect to such fiscal year, or written representations that no Forms 5 were required, we believe that the following is the list of our officers, directors and greater than ten percent beneficial owners who have failed to file on a timely basis all Section 16(a) filing requirements during the fiscal year ended December 31, 2021: Carl Schwartz 1 late reporting and 1 late amendment covering 1 transaction; Charles Lee Nuzum Sr 2 late reporting covering 2 transactions; Christina Lee Jenkins MD 2 late reporting covering 2 transactions; and Raymond Vennare 1 late reporting covering 1 transaction.

 

Code of Ethics

 

We have adopted a Code of Ethics that applies to all of our employees, officers (including our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions) and directors. Our Code of Ethics satisfies the requirements of Item 406(b) of Regulation S-K and is included as an exhibit to this Form 10-K.

 

ITEM 11. EXECUTIVE COMPENSATION.

 

Overview

 

This section describes the material elements of the compensation awarded to, earned by or paid to our Chief Executive Officer and our Chief Financial Officer, collectively referred to as the “Named Executive Officers.” We did not have any other executive officers, as determined in accordance with SEC rules, during 2020. 

 

Summary Compensation Table for Fiscal 2021 and 2020

 

The following table provides information regarding the compensation earned during the fiscal years ended December 31, 2021 and December 31, 2020 by each of the Named Executive Officers:

 

50

 

Name and
Principal
Position

Year

 

Salary

   

Bonus

   

(1)
Stock
Awards

   

(1)
Option
Awards

   

All Other
Compensation

   

Total
Compensation

 
                                                   

J. Melville Engle (2)

2021

  $ 391,342     $ -     $ -     $ -     $ -     $ 391,342  
                                                   

Carl Schwartz, CEO (3)

2021

  $ 541,827     $ -     $ 582,280     $ -     $ 163,493     $ 1,287,600  
 

2020

  $ 430,000     $ -     $ 46,002     $ -     $ -     $ 476,002  
                                                   

Bob Myers, CFO (4)

2021

  $ 371,965     $ 20,000     $ 37,667     $ -     $ -     $ 429,632  
 

2020

  $ 327,838     $ -     $ 15,334     $ -     $ -     $ 343,172  

 

 

(1)

Represents the actual compensation cost granted during 2021 and 2020 as determined pursuant to FASB ASC 718, Stock Compensation.

     
 

(2)

On March 19, 2021 Mr. Engle was named Chief Executive Officer. Mr. Engle received an annual salary of $475,000. Mr. Engle is eligible for a Long-Term Incentive Program (“LTIP”) structured to reward performance. The LTIP awards will each vest after three years (rolling) subject to continued employment, with the amount that vests to be based on two or more measures of employment performance, including shareholder return (increase in common stock price and accomplishment of profit budgets). The LTIP awards consist of 300,000 Restricted Stock Unit’s (“RSU’s”). Each RSU awards consists of three equal tranches, corresponding to the three years in the performance period. The level of vesting for each tranche will vary based on (1) the level of achievement of performance goals for the corresponding fiscal year and (2) continued employment of Mr. Engle through January 1, 2024. On February 28, 2022, Mr. Engle received an annual salary increase to $524,400. Mr. Engle received a 2021 bonus of $191,760, paid in 2022.

     
 

(3)

Effective as of March 19, 2021, Dr. Schwartz resigned as Chief Executive Officer. Dr. Schwartz received a retirement package for $460,000 in base salary, unused accrued vacation for $81,827 and the vesting of all RSU’s equaling 400,000 shares of POAI common stock, par value $0.01. Additionally, Dr. Schwartz received interest payments completing his original loan debt from prior years. Dr. Schwartz received a salary increase to $460,000 annually on September 23, 2020 retroactively effective to July 1, 2020. Dr. Schwartz received 300,000 restricted stock units on September 23, 2020, payable in shares of common stock and vesting in equal annual installments over three years.

     
 

(4)

Mr. Myers received a cash bonus of $20,000 in 2021 awarded by the Board of Directors. Mr. Myers received 23,134 shares of common stock in 2021, due to vesting of his September 23, 2020 RSU’s. Mr. Myers is eligible for a Long-Term Incentive Program (“LTIP”) structured to reward performance. The LTIP awards will each vest after three years (rolling) subject to continued employment, with the amount that vests to be based on two or more measures of employment performance, including shareholder return (increase in common stock price and accomplishment of profit budgets). The LTIP awards consist of 150,000 Restricted Stock Unit’s (“RSU’s”). Each RSU awards consists of three equal tranches, corresponding to the three years in the performance period. The level of vesting for each tranche will vary based on (1) the level of achievement of performance goals for the corresponding fiscal year and (2) continued employment of Mr. Myers through January 1, 2024. On February 28, 2022, Mr. Myers received an annual increase to $380,880. Mr. Myers received a 2021 bonus of $106,950, paid in 2022. Mr. Myers received a salary increase to $345,000 annually on September 23, 2020 retroactively effective to July 1, 2020. Mr. Myers received 100,000 restricted stock units on September 23, 2020, payable in shares of common stock and vesting in equal annual installments over three years.

 

Outstanding Equity Awards at Fiscal Year-end for Fiscal 2021

 

The following table sets forth certain information regarding outstanding equity awards held by the named executive officers as of December 31, 2021:

 

51

 

Options

   

Restricted Stock Units

 
 

Grant Date

 

Number of
Securities
Underlying
Options
Exercisable

 

Number of
Securities
Underlying
Options
Unexercisable

 

Option
Exercise
Price

   

Option
Expiration
Date

   

Number of
Units of
Stock That
Have Not
Vested

   

Market Value

Of Units of Stock
That Have

Not Vested

 
                                               

J. Melville Engle

12/31/2016

    179         $ 28.00    

12/31/2026

             
 

3/31/2017

    238         $ 21.00    

3/31/2027

             
 

6/22/2017

    12,500         $ 14.70    

6/22/2027

             
 

6/30/2017

    340         $ 14.70    

6/30/2027

             
 

9/30/2017

    344         $ 14.54    

9/30/2027

             
 

12/31/2017

    2,475         $ 10.10    

12/31/2027

             
 

3/31/2018

    455         $ 11.00    

3/31/2028

             
 

6/30/2018

    443         $ 11.30    

6/30/2028

             
 

9/30/2018

    472         $ 10.60    

9/30/2028

             
 

12/31/2018

    4,038         $ 6.19    

12/31/2028

             
 

3/31/2019

    667         $ 7.50    

3/31/2029

             
 

4/4/2019

    12,500         $ 7.48    

4/4/2029

             
 

6/30/2019

    669         $ 7.48    

6/30/2029

             
 

9/30/2019

    990         $ 5.05    

9/30/2029

             
 

12/31/2019

    13,410         $ 2.61    

12/31/2029

             
 

3/31/2020

    3,174         $ 1.58    

3/31/2030

             
 

4/3/2020

    15,267         $ 1.31    

4/3/2030

             
 

6/30/2020

    3,049         $ 1.64    

6/30/2030

             
 

9/30/2020

    6,142         $ 0.81    

9/30/2030

             
 

12/31/2020

    47,788         $ 0.73    

12/31/2030

             
 

5/17/2021

    -           -       -       300,000     $ 285,570  
                                               

Carl Schwartz

7/19/2013

    7         $ 1.54    

7/19/2023

             
 

6/30/2015

    26         $ 1.54    

6/30/2025

             
 

6/30/2015

    26         $ 775.00    

6/30/2025

             
 

3/31/2016

    59         $ 42.50    

3/31/2026

             
 

6/30/2016

    133         $ 37.50    

6/30/2026

             
 

9/30/2016

    121         $ 41.25    

9/30/2026

             
 

12/31/2016

    179         $ 1.54    

12/31/2026

             
 

12/31/2016

    714         $ 28.00    

12/31/2026

             
 

3/31/2017

    238         $ 21.00    

3/31/2027

             
 

6/22/2017

    37,689         $ 1.54    

6/22/2027

             
 

11/10/2017

    2,834         $ 1.54    

11/10/2027

             
 

1/2/2018

    14,175         $ 1.54    

1/2/2028

             
 

6/30/2018

    12,168         $ 1.54    

6/30/2028

             
 

8/1/2018

    4,490         $ 1.54    

8/1/2028

             
 

1/2/2019

    32,305         $ 1.54    

1/2/2029

             
 

4/4/2019

    20,000         $ 1.54    

4/4/2029

             
 

7/1/2019

    4,219         $ 7.90    

7/1/2029

             
 

8/1/2019

    5,128         $ 6.50    

8/1/2029

             
 

9/1/2019

    6,050         $ 5.51    

9/1/2029

             
 

3/31/2020

    3,174         $ 1.58    

3/31/2030

             
 

6/30/2020

    3,049         $ 1.64    

6/30/2030

             
 

9/30/2020

    6,142         $ 0.81    

9/30/2030

             
 

12/31/2020

    20,481         $ 0.73    

12/31/2030

             
                                               

Bob Myers

8/13/2012

    53         $ 1.54    

8/13/2022

             
 

3/18/2013

    42         $ 1.54    

3/18/2023

             
 

3/6/2014

    14         $ 1.54    

3/6/2024

             
 

9/16/2016

    357         $ 1.54    

9/16/2026

             
 

6/22/2017

    30,411         $ 1.54    

6/22/2027

             
 

4/4/2019

    16,600         $ 1.54    

4/4/2029

             
 

9/23/2020

                          66,666     $ 63,459  
 

5/17/2021

                          150,000     $ 142,785  

 

52

 

Executive Compensation Components for Fiscal 2021

 

Base Salary. Base salary is an important element of our executive compensation program as it provides executives with a fixed, regular, non-contingent earnings stream to support annual living and other expenses. As a component of total compensation, we generally set base salaries at levels believed to attract and retain an experienced management team that will successfully grow our business and create stockholder value. We also utilize base salaries to reward individual performance and contributions to our overall business objectives but seek to do so in a manner that does not detract from the executives’ incentive to realize additional compensation through our stock options.

 

The Compensation Committee reviews the Chief Executive Officer’s salary at least annually. The Compensation Committee may recommend adjustments to the Chief Executive Officer’s base salary based upon the Compensation Committee’s review of his current base salary, incentive cash compensation and equity-based compensation, as well as his performance and comparative market data. The Compensation Committee also reviews other executives’ salaries throughout the year, with input from the Chief Executive Officer. The Compensation Committee may recommend adjustments to other executives’ base salary based upon the Chief Executive Officer’s recommendation and the reviewed executives’ responsibilities, experience, and performance, as well as comparative market data.

 

In utilizing comparative data, the Compensation Committee seeks to recommend salaries for each executive at a level that is appropriate after giving consideration to experience for the relevant position and the executive’s performance. The Compensation Committee reviews performance for both our Company (based upon achievement of strategic initiatives) and each individual executive. Based upon these factors, the Compensation Committee may recommend adjustments to base salaries to better align individual compensation with comparative market compensation, to provide merit-based increases based upon individual or company achievement, or to account for changes in roles and responsibilities.

 

Bonuses. Until 2018, the Chief Financial Officer received 20% contractual cash bonuses. Any other bonus for the CFO, as well as for the CEO, if offered, were determined by the Compensation Committee. The bonuses in past years were a combination of cash and employee stock options. The CFO signed an amended contract whereby the contractual bonuses were removed subsequent to August 1, 2018. All bonuses subsequent to 2018 are part of a structured program established by the Compensation Committee and approved by the Board of Directors.

 

Stock Options and Other Equity Grants. Consistent with our compensation philosophies related to performance-based compensation, long-term stockholder value creation and alignment of executive interests with those of stockholders, we make periodic grants of long-term compensation in the form of stock options to our executive officers, directors and others in the organization.

 

Stock options provide executive officers with the opportunity to purchase common stock at a price fixed on the grant date regardless of future market price. A stock option becomes valuable only if the common stock price increases above the option exercise price and the holder of the option remains employed during the period required for the option shares to vest. This provides an incentive for an option holder to remain employed by us. In addition, stock options link a significant portion of an employee’s compensation to stockholders’ interests by providing an incentive to achieve corporate goals and increase stockholder value. Under our Amended and Restated 2012 Stock Incentive Plan (the “2012 Plan”), we may also make grants of restricted stock awards, restricted stock units, performance share awards, performance unit awards and stock appreciation rights to officers and other employees. We adopted the 2012 Plan to give us flexibility in the types of awards that we could grant to our executive officers and other employees. 

 

53

 

Amendment to Stock Option Plan. On September 3, 2020, our stockholders approved amendments to the 2012 Plan to increase the share reserve under the 2012 Plan by an aggregate 750,000 shares from the most recent reserve of 1,000,000 shares to an aggregate 1,750,000 shares. On August 17, 2021, our stockholders approved amendments to the 2012 Plan to increase the share reserve under the 2012 Plan by an aggregate 1,500,000 shares from the most recent reserve of 1,750,000 shares to an aggregate 3,250,000 shares. As of December 31, 2021, options to purchase 1,062,871 shares of common stock are subject to outstanding stock options under the 2012 Plan. In determining the amount of the increase in the 2012 Plan, the Board took into account its intention to grant further equity awards to current and future executive officers and key employees and directors.

 

Restricted Stock Units. Consistent with our compensation philosophies related to performance-based compensation, long-term stockholder value creation and alignment of executive interests with those of stockholders, we make periodic grants of long-term compensation in the form of restricted stock units to our executive officers.

 

Restricted stock units provide executive officers with stock that is not fully transferable until certain conditions are met. Upon satisfaction of the conditions, the stock is no longer restricted, and becomes transferable to the officer.

 

Limited Perquisites; Other Benefits. We provide our employees with a full complement of employee benefits, including health and dental insurance, short term and long-term disability insurance, life insurance, a 401(k) plan, FSA flex plan and Section 125 plan.

 

Long Term Incentive Plan for Executive Officers

 

On May 17, 2021, the Committee adopted and approved a 2021 Long Term Incentive Plan (the “LTIP”) to provide appropriate incentives to the Company’s executive officers over the critical three-year performance period consisting of fiscal years 2021, 2022 and 2023. Under the LTIP, the Company granted restricted stock units (“RSUs”) to the Company’s current CEO, J. Melville Engle, and its CFO, Bob Myers, pursuant to the Company’s Amended and Restated 2012 Stock Incentive Plan (as amended, the “Stock Incentive Plan”).

 

The LTIP awards consist of 300,000 RSUs for the CEO and 150,000 RSUs for the CFO granted as of May 17, 2021. Each RSU award consists of three equal tranches, corresponding to the three years in the performance period. These RSUs will vest on January 1, 2024, with the level of vesting of each tranche based on (1) the level of achievement of performance goals for the corresponding fiscal year (see below) and (2) continued employment of the executive through January 1, 2024. For each tranche, the RSUs will vest at the 100% level for performance at the target level; 50% for performance at the threshold level (with no vesting below the threshold level); and 150% for maximum performance (in other words, for maximum performance on both performance components in a fiscal year, the payout for that year would be 150% of the number of RSUs in the corresponding tranche). The level of vesting for each component is prorated between the threshold level and the target level, and between the target level and the maximum level. To the extent vested, the awards will vest on or before March 15, 2024, following the determination of the Company’s earnings per share in 2023.

 

 Performance-based vesting of the RSUs in the tranche for each fiscal year (100,000 RSUs per year for the CEO and 50,000 RSUs per year for the CFO) will be based equally on two components of performance:

 

 

(1)

Stock Price. A stock price component is based on the average closing share price of the Company’s common stock over the last 20 trading days of the fiscal year, as set forth in the LTIP.

     
 

(2)

Earnings (Loss) Per Share. An earnings component is based on the Company’s earnings (loss) per common share for that fiscal year, as set forth in the LTIP.

 

If the Committee determines that circumstances have changed and modification is required to reflect the original intent of the performance goals, the Committee may in its discretion increase (but not decrease) the number of RSUs that vest for any of the covered years.

 

On August 10, 2021, the stockholders approved an amendment to the Amended and Restated 2012 Stock Incentive Plan to increase the reserve of shares of common stock authorized for issuance thereunder by 1,500,000, to 3,250,000 shares. Therefore, all RSUs awarded under the LTIP will be paid in shares of common stock, rather than cash payments that might have been required had such plan amendment not been approved.

 

54

 

Employment Contracts

 

Employment Agreement with Former Chief Executive Officer.

 

On November 10, 2017, we entered into an employment agreement with Dr. Carl Schwartz, who has served as Chief Executive Officer from December 1, 2016 through March 19,2021. Under the agreement, the employment of Dr. Schwartz is at will.

 

On July 1, 2019, we entered into an amended employment agreement with Dr. Schwartz. The annualized base salary for Dr. Schwartz was $400,000 for both 2019 and 2018. Such base salary may be adjusted by us but may not be reduced except in connection with a reduction imposed on substantially all employees as part of a general reduction.

 

On September 23, 2020, the Compensation Committee of the Board of Directors of the Company approved the elements of a compensation program for the executive officers of the Company. The base salaries of the executive officers were increased by 15%, effective as of July 1, 2020, resulting in annualized base salaries of $460,000 for Dr. Schwartz. In addition, Dr. Schwartz was awarded a one-time, special interim grant of retention equity awards for 2020 on September 23, 2020 of 300,000 restricted stock units payable in shares of common stock and vesting in equal annual installments over three years, subject to continued employment, with accelerated vesting upon certain events, including involuntary termination without cause, voluntary termination for good reason or retirement after at least eighteen months upon at least six months’ notice.

 

Retirement of Former Chief Executive Officer

 

On March 19, 2021, Dr. Schwartz retired through his resignation as the Chief Executive Officer of the Company. In connection with the resignation, Dr. Schwartz and the Company simultaneously entered into a Transition and Separation Agreement pursuant to which, among other things, Dr. Schwartz agreed to retire from his employment and resign as a member of the Board and to provide certain transition services to the Company in exchange for the issuance to Dr. Schwartz of 100,000 shares of common stock. The Company and Dr. Schwartz also entered into an Agreement and Release pursuant to which, among other things, Dr. Schwartz and the Company released each other from any and all claims each may have against the other, and the Company agreed to provide Dr. Schwartz with certain separation benefits, including $460,000 (gross) in severance pay, equal to one year of his base salary, and the vesting of the 300,000 restricted stock units previously granted to Dr. Schwartz.

 

Employment Agreement with Current Chief Executive Officer

 

On April 5, 2021, the Company and J. Melville Engle, the Company’s current Chief Executive Officer, entered into an Employment Agreement (the “Agreement”) effective as of March 19, 2021, the first date of Mr. Engle’s employment. Pursuant to the Agreement, Mr. Engle is entitled to an annual base salary of $475,000. He will also be eligible (i) to receive an annual cash bonus equal to up to 50% of his salary, or at the discretion of the Compensation Committee (the “Committee”) of the Company’s Board of Directors, a higher percentage based on his performance and (ii) to participate in a long-term incentive plan to be adopted and maintained by the Committee. Under the LTIP, Mr. Engle will receive 100,000 restricted shares of Company common stock or restricted stock units for each of the next three calendar years of his employment, vesting over three years and subject to continued employment, with the amount that vests to be based on his performance. Mr. Engle will also be eligible to participate in the standard employee benefit plans generally available to executive employees of the Company, and, at the discretion of the Committee, to receive grants of stock options or other equity awards. Any grants of equity awards, including those above, will be made from the Company’s Amended and Restated 2012 Stock Incentive Plan or successor plans.

 

Under the Agreement, Mr. Engle’s employment by the Company is at-will. If his employment is terminated by the Company without “cause” or if he voluntarily resigns with “good reason” (in each case as defined in the Agreement), then Mr. Engle will be entitled to receive from the Company payment of his base salary then in effect through his last date of employment, plus accrued, unused vacation pay. In addition, Mr. Engle will be entitled to (a) severance pay in an amount equal to 12 months of his base salary then in effect, less applicable taxes and withholdings; and (b) a bonus payment on a pro-rata basis through the date of his termination.

 

55

 

The Agreement also contains customary provisions with respect to confidentiality and intellectual property, in addition to ones prohibiting Mr. Engle from soliciting the Company’s employees and from engaging in certain activities that are competitive with the Company for a period of 12 months after termination of his employment.

 

Employment Agreement with Chief Financial Officer.

 

On August 13, 2012, we entered into an employment agreement with Bob Myers, who has served as Chief Financial Officer since July 1, 2012. Under the agreement the employment of Mr. Myers is at will.

 

On August 20, 2018, we entered into an amendment to employment agreement with Mr. Myers. Effective August 1, 2018, Mr. Myers received an annualized base salary of $250,000. Effective August 1, 2019, Mr. Myers received an annualized base salary of $300,000.

 

On September 23, 2020, the Compensation Committee of the Board of Directors of the Company approved the elements of a compensation program for the executive officers of the Company. The base salaries of the executive officers were increased by 15%, effective as of July 1, 2020, resulting in annualized base salaries of $345,000 for Mr. Myers. In addition, Mr. Myers was awarded a one-time, special interim grant of retention equity awards for 2020 on September 23, 2020 of 100,000 restricted stock units payable in shares of common stock and vesting in equal annual installments over three years, subject to continued employment, with accelerated vesting upon certain events, including involuntary termination without cause, voluntary termination for good reason or retirement after at least eighteen months upon at least six months’ notice.

 

Base salaries for Mr. Myers may be adjusted by us but may not be reduced except in connection with a reduction imposed on substantially all employees as part of a general reduction. He will also each be eligible to receive an annual incentive bonus for each calendar year at the end of which he remains employed by us, subject to the attainment of certain objectives.

 

In addition, as a part of the compensation program approved in September 2020, Mr. Myers will be eligible for an annual bonus and a long-term incentive program effective January 1, 2021. Based on Company and personal performance vs. annual objectives to be established by the officers and the Committee and to be evaluated by the Committee, the officers will be granted an annual bonus opportunity ranging from 0% to 50% of base salary, or at the Board’s discretion, a higher percentage based on performance. Also, under the long-term incentive program, the officer will receive annual grants of restricted stock units on January 1 of each calendar year starting in 2021. Each grant will consist of 50,000 restricted stock units with vesting of each grant over three years based on performance and continued employment.

 

Mr. Myers is entitled to five (5) weeks of paid vacation per each calendar year earned ratably over each calendar year, to be taken at such times as employee and Company shall determine and provided that no vacation time shall unreasonably interfere with the duties required to be rendered by employee.

 

If we terminate his employment without cause or if he terminates his employment for “good reason,” he shall be entitled to receive us severance pay in an amount equal to:(1) before the first anniversary of the date of the agreement, three months of base salary, or (2) on or after the first anniversary of the date of the agreement, twelve months of base salary, in either case less applicable taxes and withholdings. In that event, he will receive a bonus payment on a pro-rata basis through the date of termination and any accrued, unused vacation pay. The severance pay, bonus payment, and other consideration are conditioned upon executive’s execution of a full and final release of liability. “Cause” is defined to mean: 1) that he engages in willful misconduct or fails to follow the reasonable and lawful instructions of the Board, if such conduct is not cured within 30 days after notice; 2) he embezzles or misappropriates assets from us or any of our subsidiaries; 3) his violation of his obligations in the agreement, if such conduct is not cured within 30 days after notice; 4) breach of any agreement between him and us or to which we and Mr. Myers are parties, or a breach of his fiduciary responsibility to us; 5) commission by Mr. Myers of fraud or other willful conduct that adversely affects our business or reputation; or, 6) we have a reasonable belief he engaged in some form of harassment or other improper conduct prohibited by Company policy or the law. “Good reason” is defined as (1) a material diminution in his position, duties, base salary, and responsibilities; or (2) our notice to Mr. Myers that his position will be relocated to an office which is greater than 100 miles from his prior office location. In all cases of Good Reason, he must have given notice to us that an alleged Good Reason event has occurred, and the circumstances must remain uncorrected by us after the expiration of 30 days after receipt by us of such notice.

 

56

 

During Mr. Myers employment and for twelve months thereafter, regardless of the reason for the termination, he may not engage in a competing business, as defined in the agreement and will not solicit any person to leave employment with us or solicit our clients or prospective clients with whom he worked, solicited, marketed, or obtained confidential information about during his employment with us, regarding services or products that are competitive with any of our services or products.

 

Potential Payments Upon Termination or Change of Control

 

Most of our stock option agreements provide for an acceleration of vesting in the event of a change in control as defined in the agreements and in the 2012 Stock Incentive Plan. However, the stock option agreements awarded to Bob Myers provide that upon the termination of such employee’s employment without cause or for good reason, such employee’s options shall become fully vested, and the vested shares may be purchased for up to five years after such termination (or such lesser period for the option if the remaining period of the option is less than five years after such termination). In addition, in the event of such employee’s retirement, death or disability, such employee’s options shall become fully vested, and the vested shares may be purchased for the entire remaining period of the option. Also, see “Employment Contracts” above for a description of certain severance compensation arrangements.

 

Director Compensation

 

Effective June 17, 2021 the Board adopted a Director Compensation Program under which the members of the Board of Directors receive quarterly awards of common stock and cash as compensation for their services as directors and annual awards of common stock and cash for services as committee members. These awards were implemented to replace the previous program of quarterly stock option grants to directors. The June 2020 annual common stock award remains in place as described below.

 

The compensation program pays all of the compensation in the form of stock and cash awards (with the cash component payable in additional shares at the election of the director. The cash component is equal to 28% of the total value of the award (or 38.9% of the share component of the award), intended to pay the tax on the full award.

 

Each director receives a quarterly award of $8,333 on the last day of the quarter, consisting of (i) shares with a value of $6,000 and (ii) $2,333 in cash (or additional shares).

 

For each board committee, each director receives an additional annual award of $11,112, consisting of (i) shares with a value of $8,000 and (ii) $3,112 in cash (or additional shares), payable on December 31.

 

Director compensation will continue to be paid to all members of the Board of Directors through December 31, 2021. Starting in 2022, director compensation will be limited to Non-Employee Directors (directors who are not employees of POAI or any subsidiary and who do not receive regular long-term cash compensation as consultants).

 

Effective on June 16, 2020 the Board instituted an annual common stock award for all the directors under which they will receive $7,000 in value of newly issued shares of common stock, par value $0.01 per year annually for three years, as long as they are serving as a director at the annual appointment date. Additionally, the directors will receive a $3,000 cash payment per year annually for three years, as long as they are serving as a director at the annual appointment date.

 

Effective on April 3, 2020 the Board instituted an annual stock options award program for the Chairman of the Board under which he/she will be awarded options to purchase $20,000 worth of shares of common stock, par value $0.01 at an exercise price determined by the close on April 2 or the last trading day prior to April 3.

 

Prior to April 3, 2020, the Company maintained a quarterly and an annual stock options award program for all the directors under which they will be awarded options to purchase $5,000 worth of shares of common stock, par value $0.01 per quarter at an exercise price determined by the close on the last day of the quarter. Additionally, the directors that served on a committee received options to purchase $10,000 worth of shares of common stock, par value $0.01 annually, per committee served, at an exercise price determined by the close on the last day of the year.

 

57

 

Director Compensation Table for Fiscal 2021

 

The following table summarizes the compensation paid to each director in the fiscal year ended December 31, 2021:

 

   

Fees Paid or
Earned in Cash

   

Stock

Awards (1)

   

Option
Awards

   

Total

 

J. Melville Engle

  $ 9,999     $ 44,447 (2)   $ -     $ 54,446  

Charles Nuzum Sr.

  $ -     $ 76,668 (3)   $ -     $ 76,668  

Daniel Handley

  $ 15,454     $ 39,003 (4)   $ -     $ 54,457  

Greg St. Clair Sr.

  $ 8,455     $ 49,000 (5)   $ -     $ 57,455  

Nancy Chung-Welch

  $ 24,668     $ 55,003 (6)   $ -     $ 79,671  

Christina Jenkins

  $ 13,111     $ 38,452 (7)   $ -     $ 51,563  

Raymond Vennare</